All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Mapping diseases onto molecular interaction networks (such as the protein-protein interaction network, also known as the *interactome*), has contributed to the elucidation of disease mechanisms and the identification of new disease-associated genes \[[@pone.0224448.ref001], [@pone.0224448.ref002]\]. Evidence suggests that disease-associated genes are not randomly distributed within the interactome, but instead they work coordinately forming connected communities linked to disease phenotypes \[[@pone.0224448.ref001], [@pone.0224448.ref003]--[@pone.0224448.ref005]\]. Furthermore, genes expressed in a particular tissue tend to form a well-localized subnetwork, and the partition of the complete interactome into tissue-specific subnetworks has important implications for the understanding of disease mechanisms \[[@pone.0224448.ref006]\]. Gene activity is often dependent on tissue context, and human diseases arise from the complex interplay of tissue and cell-lineage-specific processes \[[@pone.0224448.ref007], [@pone.0224448.ref008]\]. Disease-associated genes are usually tissue-specific and their interaction patterns with other genes change in diseased tissues as compared to healthy ones \[[@pone.0224448.ref009]\]. These observations make elucidating the context-specific role of genes in pathophysiological processes particularly challenging \[[@pone.0224448.ref010], [@pone.0224448.ref011]\]. Exploiting tissue-specific information has provided valuable clues on tissue-specific gene functions \[[@pone.0224448.ref012]\].

The computational analysis of tissue-specific cellular networks helps to understand the tissue-specific mechanisms of diseases, and how those mechanisms interplay with one another. Authors have long hypothesized that perturbations of cellular networks are key to many phenotypic and pathophenotypic outcomes \[[@pone.0224448.ref001], [@pone.0224448.ref004], [@pone.0224448.ref013]--[@pone.0224448.ref016]\]. Because of this, co-morbid and multi-morbid phenotypes are expected to share tissue-specific causative mechanisms \[[@pone.0224448.ref012], [@pone.0224448.ref013]\]. Studies have found that multimorbidity between metabolic diseases can be explained by shared cellular mechanisms \[[@pone.0224448.ref017]\], and that multimorbidities do not necessarily imply that the involved diseases are linked through shared genes \[[@pone.0224448.ref016], [@pone.0224448.ref018]--[@pone.0224448.ref020]\].

In a previous work, we uncovered significant patterns of network connectivity between the cellular networks associated to asthma (A), dermatitis (D) and rhinitis (R) \[[@pone.0224448.ref021]\], which supported the idea that A, D and R form a multimorbidity cluster due to shared genes \[[@pone.0224448.ref022], [@pone.0224448.ref023]\] and pathomechanisms \[[@pone.0224448.ref024]--[@pone.0224448.ref026]\]. While eosinophils have been singled out as prominent mediators in a number of inflammatory diseases \[[@pone.0224448.ref027]--[@pone.0224448.ref030]\] and multimorbidities \[[@pone.0224448.ref031]--[@pone.0224448.ref034]\], many other cell types (e.g. macrophages, monocytes/dendritic cells, lymphocytes), are involved in complex and heterogeneous diseases such as A, D and R \[[@pone.0224448.ref035]--[@pone.0224448.ref037]\]. Yet, a cell-type-based interactome analysis of the allergic multimorbidity has not been reported to the best of our knowledge. In this study, we use the interactome and expression data to investigate the mechanisms of multimorbidity between A, D and R at a cell-type-specific level, focusing on emergent non-eosinophilic allergy-mediating cell types across distinct tissues. Our results provide new insights could provide valuable information to improve prevention and treatment of these diseases.

Methods {#sec006}
=======

Methods are described in detail in [S1 Text](#pone.0224448.s014){ref-type="supplementary-material"}.

Data sources {#sec007}
------------

### Gene-disease associations {#sec008}

We built the sets of genes associated to A, D and R by integrating data from four sources: (1) The Comparative Toxicogenomics Database \[[@pone.0224448.ref038]\], which provides highly reliable gene-disease associations characterized through various experimental procedures combined with a process of expert curation of the literature and other databases (e.g. OMIM \[[@pone.0224448.ref039]\]). (2) The DisGeNet catalog, that contains curated gene-disease associations extracted from literature \[[@pone.0224448.ref040]\]. (3) UniProt-derived gene-disease associations, extracted from the *Involvement in disease* section of the Uniprot Knowledgebase \[[@pone.0224448.ref041]\]. (4) The Phenotype-Genotype Integrator database, that integrates information various NCBI genomic databases with association data from the National Human Genome Research Institute GWAS Catalog \[[@pone.0224448.ref042]\]. This is the only data source containing solely GWAS-derived gene associations \[[@pone.0224448.ref043]\]. Genes associated to a disease *d* (any of A, D or R) will be hereinafter referred to as *d*-associated genes.

### The interactome {#sec009}

We built the functional interaction network (hereinafter called the *interactome* for brevity) by combining data from: (1) The Reactome Functional Interaction Network (v. 022717) \[[@pone.0224448.ref044]\], which includes not only protein-protein interactions but also gene expression interaction, metabolic interactions and signal transduction. (2) The STRING interaction network (v.10.5) \[[@pone.0224448.ref045]\].

### Cell-type-specific gene expression {#sec010}

Gene expression levels were obtained from the human gene expression atlas available at ArrayExpress under accession number E-MTAB-62 \[[@pone.0224448.ref046]\]. This is a cell-type-wide compendium of high-quality microarray-derived expression data that has been previously used in other network-based analysis of gene expression \[[@pone.0224448.ref047]--[@pone.0224448.ref049]\] and has been incorporated into a number of biomedical software packages \[[@pone.0224448.ref050]--[@pone.0224448.ref052]\]. We filtered the data to remove redundancies and samples subjected to particular treatments or environmental factors (see [S1 Text](#pone.0224448.s014){ref-type="supplementary-material"}). We then centered and standardized the expression level of each gene as: $$e_{g,c} = \frac{\left( {E_{g,c} - M_{g}} \right)}{MAD_{g}}$$ where *E*~*g*,*c*~ is the expression level of the gene *g* in cell type *c*, *M*~*g*~ is the median expression level the gene *g* across all cell types, and *MAD*~*g*~ is the median absolute deviation of the expression levels of gene *g* across all cell types. This made the expression levels comparable between genes \[[@pone.0224448.ref053], [@pone.0224448.ref054]\].

We defined a gene to be cell-type-specific if its absolute normalized expression level *e*~*g*,*c*~ was at least 1.5 larger than the interquartile range (IQR) of its normalized expression across all cell types \[[@pone.0224448.ref006], [@pone.0224448.ref012], [@pone.0224448.ref055], [@pone.0224448.ref056]\]. Genes specific to a cell type *c* (any of our cell types of interest) will be hereinafter referred to as *c*-specific genes.

Cellular pathways {#sec011}
-----------------

Cellular pathways were downloaded from Reactome database in the *UniProt2Reactome* format files \[[@pone.0224448.ref044]\]. Pathway-associated genes either without expression data or not present in the interactome were not considered. Disease-related cellular pathways (e.g. *Constitutive Signaling by Aberrant PI3K in Cancer*) were not considered. Reactome is a collection of pathways built in a hierarchical manner, where larger pathways are subdivided into smaller pathways with more specific functionalities. This implies a trade-off between the specificity in the representation of cellular functions and the average number of genes per pathway \[[@pone.0224448.ref057]\]. To minimize the overlap between pathways in order to avoid redundancies that could negatively affect our analysis \[[@pone.0224448.ref058]\], we calculated the pairwise overlap between pathways at distinct levels of the Reactome hierarchy using the Sorensen-Dice method \[[@pone.0224448.ref059]--[@pone.0224448.ref061]\]. If two pathways had an overlap of \> 50% genes, the one with the lowest number of associated genes was removed from the set. We chose pathways of at depth 3 of the hierarchy because it provided a mean overlap \< 1% while annotating 4,809 genes (this is 87,9% of the total genes annotated in the database, all levels considered). Genes associated to a pathway *p* (any of our pathways of interest) will be hereinafter referred to as *p*-associated genes.

Pathway annotation in our previous study of A, D and R were extracted from BioCarta \[[@pone.0224448.ref062]\]. There is not a perfect equivalence between cellular pathways from BioCarta and Reactome databases, so in order to compare our results to those from our previous whole-organism multimorbidity study \[[@pone.0224448.ref021]\] we performed an association test to identify which BioCarta pathways significantly overlapped with Reactome pathways (Fisher's Exact test, adjusted *P* \<0.05; [S1 Table](#pone.0224448.s003){ref-type="supplementary-material"}). *P*-values in this study were adjusted by the Benjamini-Hochberg method for false discovery (FDR) control \[[@pone.0224448.ref063]\].

Cell-type-specific networks {#sec012}
---------------------------

In order to generate the specific network for any cell type *c*, we selected all edges from the interactome connecting *c*-specific genes \[[@pone.0224448.ref006], [@pone.0224448.ref064]\]. Because of the interactome-based nature of our analysis, those genes not present in the interactome or not present in the expression dataset were removed from the analysis. The statistical significance of the number of *d*-associated genes present in each *c*-specific network was calculated by means of a Fisher's Exact test (adjusted *P* \<0.05).

Quantifying cell-type-specific multimorbidity {#sec013}
---------------------------------------------

In order to obtain a quantitative measure of the extent to which A, D and R multimorbidity is manifested in distinct cell types, we designed an interactome-based approach (workflow in [Fig 1](#pone.0224448.g001){ref-type="fig"}; illustrated with an example in [S1 Fig](#pone.0224448.s001){ref-type="supplementary-material"}). Briefly, we scored all genes specific to a given cell type according to their connectivity (or their \"closeness\") to known disease-associated genes, under the rationale that the malfunction of one (or more) of the disease-associated genes is likely to perturb the function of the neighboring genes, eventually disrupting a cellular mechanism and giving rise to a diseased phenotype \[[@pone.0224448.ref005], [@pone.0224448.ref065]--[@pone.0224448.ref068]\]. In other words, we scored each gene in each cell type according to its contribution to the manifestation of A, D and R. Then, we selected the set of top-scoring genes (called *S*; *S*^*c*^~*d*~ being the top-scoring genes for disease *d* in cell type *c*). Finally, for each cell type we calculated the overlap between the sets of top-scoring genes for AD, AR, DR and ADR. This overlap was called the Multimorbidity Score (*MS; MS*^*T*^~*d1*,*d2*~ being the Multimorbidity Score for diseases *d1* and *d2* in cell type *c*). The process is described in detail in [S1 Text](#pone.0224448.s014){ref-type="supplementary-material"}.

![Workflow for *Quantifying cell-type-specific multimorbidity* section.\
Only multimorbidity between two diseases is shown. Numbered circles indicate the steps of in the section *Quantifying cell-type-specific multimorbidity* in *Methods*.](pone.0224448.g001){#pone.0224448.g001}

Characterizing cell-type-specific multimorbidity mechanisms {#sec014}
-----------------------------------------------------------

After having quantitatively scored the multimorbidity between diseases in different cell types, we wished to identify the actual cellular mechanisms involved in the manifestation of the multimorbidities. To do so, we designed a method to measure the perturbation that a disease can exert over a cellular pathway in a given cell type. The starting point is the set of top-scoring genes *S*^*c*^~*d*~ calculated in the previous section. We identified the set of cellular pathways present in cell type *c*, and then scored how perturbed they were by the manifestation of disease *d* using *S*^*c*^~*d*~ (workflow in [Fig 2](#pone.0224448.g002){ref-type="fig"}; illustrated with an example in [S2 Fig](#pone.0224448.s002){ref-type="supplementary-material"}). This score was called the Perturbation Score (*PS; PS*^*c*^~*p*,*d*~ being the perturbation experimented by pathway *p* during the manifestation of disease *d* on cell type *c*). Under the assumption that any disease can be viewed as the product of perturbed cellular mechanisms (i.e. cellular pathways), and that multimorbidity is known to arise as those perturbed mechanisms are shared by distinct diseases \[[@pone.0224448.ref012], [@pone.0224448.ref013], [@pone.0224448.ref069], [@pone.0224448.ref070]\], we selected as candidate mechanisms for multimorbidity those pathways that were significantly perturbed in more than one disease in the same cell type. The process is described in detail in [S1 Text](#pone.0224448.s014){ref-type="supplementary-material"}.

![Workflow for *Characterizing cell-type-specific multimorbidity mechanisms* section.\
Only multimorbidity between two diseases is shown. Numbered circles indicate the steps of in the section *Characterizing cell-type-specific multimorbidity mechanisms* in *Methods*.](pone.0224448.g002){#pone.0224448.g002}

Identifying cell-type-specific candidates to multimorbidity {#sec015}
-----------------------------------------------------------

Lastly, we wished to identify individual genes that might constitute candidates to multimorbidity. In the *Quantifying cell-type-specific multimorbidity* section we had identified the sets of genes more susceptible to be perturbed by a disease in a cell type (*S*^*c*^~*d*~). We identified as multimorbidity candidates those genes simultaneously belonging to \> = 2 of those sets (i.e. susceptible to be perturbed by two diseases in the same cell type) for AD, AR, DR multimorbidities, and \> = 3 in the case of ADR multimorbidity. In addition, we numerically scored the contribution of each gene *g* to multimorbidity (*MS*^*g*,*c*^~*d1*,*d2*~ being the Multimorbidity Score for gene *c* with respect to diseases *d1* and *d2* in cell type *c*). This process is detailed in **Text S1**.

Results {#sec016}
=======

Gene-disease associations {#sec017}
-------------------------

The number of genes associated to A, D and R with representation in the interactome and expression data was 98, 62 and 10, respectively. The complete list of genes is shown in [Table 1](#pone.0224448.t001){ref-type="table"} (see [S2 Table](#pone.0224448.s004){ref-type="supplementary-material"} and *Gene-disease associations* in the [Methods](#sec006){ref-type="sec"} section for data sources). Three genes were associated with A, D and R: *IL13*, platelet-activating factor acetylhydrolase *PLA2G7* and *LRRC32*, a signal peptide cleavage essential for surface expression of a regulatory T cell surface protein. The complete list of all disease-associated genes in each cell type is provided in [S2 Table](#pone.0224448.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0224448.t001

###### Gene-disease associations.

![](pone.0224448.t001){#pone.0224448.t001g}

  gene name     A   D   R   gene description                                                  gene name          A   D   R   gene description
  ------------- --- --- --- ----------------------------------------------------------------- ------------------ --- --- --- ------------------------------------------------------------------
  *IL13*        ●   ●   ●   interleukin 13                                                    *MMP9*             ●           matrix metallopeptidase 9
  *LRRC32*      ○   ○   ○   leucine rich repeat containing 32                                 *MS4A2*            ●           membrane spanning 4-domains A2
  *PLA2G7*      ●   ●   ●   phospholipase A2 group VII                                        *MYB*              ●           MYB proto-oncogene, transcription factor
  *CASP8*       ●   ●       caspase 8                                                         *NDFIP1*           ○           Nedd4 family interacting protein 1
  *CCL11*       ●   ●       C-C motif chemokine ligand 11                                     *NFKB2*            ●           nuclear factor kappa B subunit 2
  *CD14*        ●   ●       CD14 molecule                                                     *NOS2*             ●           nitric oxide synthase 2
  *CHI3L1*      ●   ●       chitinase 3 like 1                                                *NPY*              ●           neuropeptide Y
  *CRNN*        ○   ○       cornulin                                                          *PARP1*            ●           poly(ADP-ribose) polymerase 1
  *EFHC1*       ○   ○       EF-hand domain containing 1                                       *PEX14*            ○           peroxisomal biogenesis factor 14
  *ETS1*        ○   ○       ETS proto-oncogene 1, transcription factor                        *PHF11*            ●           PHD finger protein 11
  *IL18R1*      ○   ○       interleukin 18 receptor 1                                         *PLAU*             ●           plasminogen activator, urokinase
  *IL1B*        ●   ●       interleukin 1 beta                                                *PPP2CA*           ●           protein phosphatase 2 catalytic subunit alpha
  *IL33*        ●   ●       interleukin 33                                                    *PTEN*             ●           phosphatase and tensin homolog
  *IL4*         ●   ●       interleukin 4                                                     *PTGES*            ○           prostaglandin E synthase
  *IL5*         ●   ●       interleukin 5                                                     *PTGS2*            ●           prostaglandin-endoperoxide synthase 2
  *IL6R*        ○   ○       interleukin 6 receptor                                            *RNASE3*           ●           ribonuclease A family member 3
  *IRAK3*       ●   ●       interleukin 1 receptor associated kinase 3                        *RORA*             ○           RAR related orphan receptor A
  *KIF3A*       ●   ○       kinesin family member 3A                                          *SCGB1A1*          ●           secretoglobin family 1A member 1
  *RAD50*       ●   ○       RAD50 double strand break repair protein                          *SOD1*             ●           superoxide dismutase 1
  *SPINK5*      ●   ●       serine peptidase inhibitor, Kazal type 5                          *TBX21*            ●           T-box 21
  *STAT6*       ○   ●       signal transducer and activator of transcription 6                *TBXA2R*           ●           thromboxane A2 receptor
  *TNIP1*       ●   ○       TNFAIP3 interacting protein 1                                     *TGFB1*            ●           transforming growth factor beta 1
  *IL1RL1*      ●       ○   interleukin 1 receptor like 1                                     *TIMP3*            ●           TIMP metallopeptidase inhibitor 3
  *RANBP6*      ○       ○   RAN binding protein 6                                             *TNC*              ●           tenascin C
  *SLC25A46*    ○       ○   solute carrier family 25 member 46                                *TNFSF4*           ○           TNF superfamily member 4
  *SMAD3*       ○       ○   SMAD family member 3                                              *TRPA1*            ●           transient receptor potential cation channel subfamily A member 1
  *TLR1*        ○       ○   toll like receptor 1                                              *TYRP1*            ○           tyrosinase related protein 1
  *ADCYAP1R1*   ●           ADCYAP receptor type I                                            *VEGFA*            ●           vascular endothelial growth factor A
  *ADORA1*      ○           adenosine A1 receptor                                             *CCL17*                ●       C-C motif chemokine ligand 17
  *ALDH2*       ●           aldehyde dehydrogenase 2 family (mitochondrial)                   *CCL22*                ●       C-C motif chemokine ligand 22
  *ALOX5*       ●           arachidonate 5-lipoxygenase                                       *CCL24*                ●       C-C motif chemokine ligand 24
  *AREG*        ●           amphiregulin                                                      *CCR5*                 ●       C-C motif chemokine receptor 5 (gene/pseudogene)
  *ARG1*        ●           arginase 1                                                        *CD207*                ○       CD207 molecule
  *ARG2*        ●           arginase 2                                                        *CSTA*                 ●       cystatin A
  *BACH2*       ○           BTB domain and CNC homolog 2                                      *CTLA4*                ●       cytotoxic T-lymphocyte associated protein 4
  *BCL2*        ●           BCL2, apoptosis regulator                                         *CXCL10*               ●       C-X-C motif chemokine ligand 10
  *CAT*         ●           catalase                                                          *CYP24A1*              ○       cytochrome P450 family 24 subfamily A member 1
  *CCL2*        ●           C-C motif chemokine ligand 2                                      *EMSY*                 ●       EMSY, BRCA2 interacting transcriptional repressor
  *CDH17*       ○           cadherin 17                                                       *FOXP3*                ●       forkhead box P3
  *CDK2*        ○           cyclin dependent kinase 2                                         *GLB1*                 ●       galactosidase beta 1
  *CFTR*        ●           cystic fibrosis transmembrane conductance regulator               *IFNG*                 ●       interferon gamma
  *CHIT1*       ○           chitinase 1                                                       *IL10*                 ●       interleukin 10
  *CPN1*        ●           carboxypeptidase N subunit 1                                      *IL15RA*               ○       interleukin 15 receptor subunit alpha
  *CRB1*        ○           crumbs 1, cell polarity complex component                         *IL18RAP*              ○       interleukin 18 receptor accessory protein
  *CRBN*        ○           cereblon                                                          *IL2RA*                ●       interleukin 2 receptor subunit alpha
  *CXCL14*      ●           C-X-C motif chemokine ligand 14                                   *IL6*                  ●       interleukin 6
  *CYSLTR2*     ●           cysteinyl leukotriene receptor 2                                  *IL7R*                 ○       interleukin 7 receptor
  *DNMT1*       ●           DNA methyltransferase 1                                           *KRT1*                 ●       keratin 1
  *EDN1*        ●           endothelin 1                                                      *PAH*                  ●       phenylalanine hydroxylase
  *ELF3*        ○           E74 like ETS transcription factor 3                               *PFDN4*                ○       prefoldin subunit 4
  *GPR37L1*     ○           G protein-coupled receptor 37 like 1                              *PPP2R3C*              ○       protein phosphatase 2 regulatory subunit B\'\'gamma
  *GRM4*        ○           glutamate metabotropic receptor 4                                 *PTPRN2*               ○       protein tyrosine phosphatase, receptor type N2
  *GSDMB*       ●           gasdermin B                                                       *REL*                  ○       REL proto-oncogene, NF-kB subunit
  *GSTM1*       ●           glutathione S-transferase mu 1                                    *RTEL1-TNFRSF6B*       ○       RTEL1-TNFRSF6B readthrough (NMD candidate)
  *GSTP1*       ●           glutathione S-transferase pi 1                                    *S100A8*               ●       S100 calcium binding protein A8
  *HERC2*       ○           HECT and RLD domain containing E3 ubiquitin protein ligase 2      *SELE*                 ●       selectin E
  *HMOX1*       ●           heme oxygenase 1                                                  *SLC11A1*              ●       solute carrier family 11 member 1
  *HNMT*        ●           histamine N-methyltransferase                                     *SPRR1B*               ○       small proline rich protein 1B
  *HTATIP2*     ○           HIV-1 Tat interactive protein 2                                   *SPRR3*                ○       small proline rich protein 3
  *ICAM1*       ●           intercellular adhesion molecule 1                                 *STAT1*                ●       signal transducer and activator of transcription 1
  *IKZF3*       ●           IKAROS family zinc finger 3                                       *TGM5*                 ●       transglutaminase 5
  *IL12B*       ●           interleukin 12B                                                   *TNFRSF1B*             ●       TNF receptor superfamily member 1B
  *IL1RL2*      ○           interleukin 1 receptor like 2                                     *TNXB*                 ○       tenascin XB
  *IL1RN*       ●           interleukin 1 receptor antagonist                                 *VAX2*                 ○       ventral anterior homeobox 2
  *IL2RB*       ○           interleukin 2 receptor subunit beta                               *VNN1*                 ●       vanin 1
  *KRT19*       ●           keratin 19                                                        *VNN2*                 ●       vanin 2
  *LPP*         ○           LIM domain containing preferred translocation partner in lipoma   *WAS*                  ●       Wiskott-Aldrich syndrome
  *MLLT3*       ○           MLLT3, super elongation complex subunit                           *WIPF1*                ●       WAS/WASL interacting protein family member 1
  *MMP10*       ●           matrix metallopeptidase 10                                        *BDH1*                     ○   3-hydroxybutyrate dehydrogenase 1
  *MMP13*       ○           matrix metallopeptidase 13                                        *FOXJ1*                    ●   forkhead box J1

A: asthma; D: dermatitis; R: rhinitis. Filled circle: all evidences. Empty circle: GWAS-only evidence. Only genes with expression data, present in the interactome and associated to A, D or R are shown.

Cell-type-specific gene expression and the cell-type-specific networks {#sec018}
----------------------------------------------------------------------

The complete interactome contained 15,332 genes (nodes) and 394,317 interactions (edges). The total number of cell types was 60, classified into 15 distinct tissues. The total number of genes with expression data was 8,461 (of which 7,486 were present in the interactome). [Table 2](#pone.0224448.t002){ref-type="table"} shows the number of genes specific to each cell-type-specific network and its statistical significance (an extended version of the table with *p*-values is provided as [S3 Table](#pone.0224448.s005){ref-type="supplementary-material"}). The number of genes present in a cell-type-specific network is lower than the number of cell-type-specific genes because we only considered directly connected cell-type-specific gene pairs. In other words, for a cell type *c*, any *c*-specific gene not connected to other *c*-specific gene was not a part of the *c*-specific network. The cell type with the most specific genes was *hematopoietic stem cell* with 1,156 specific genes. The cell type with the least specific genes was blood-derived *monocyte* with 132 genes. The complete list of tissues, cell types and cell-type-specific genes is available at [S2 Table](#pone.0224448.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0224448.t002

###### Number of disease-associated genes on cell-type-specific networks.

![](pone.0224448.t002){#pone.0224448.t002g}

                                                                                                        Cell-type-specific genes   Cell-type-specific network genes                                  
  ----------------------------------------------------- ----------------------------------------------- -------------------------- ---------------------------------- ----- ----- ------ ----- ----- -----
  **Adipose tissue from abdomen**                       **Adipose-derived adult stem cells (ADASCs)**   584                        319                                9     2.8   7      2.2   1     0.3
  **Adipose tissue from abdomen and thigh**             **Adipose-derived adult stem cells (ADASCs)**   645                        343                                8     2.3   5      1.5         
  **Aorta**                                             **Primary aortic smooth muscle cell**           1023                       623                                7     1.1   3      0.5         
  **Blood**                                             **721 B lymphoblasts**                          534                        329                                8     2.4   2      0.6         
  **BDCA4+ dentritic cell**                             719                                             386                        12                                 3.1   4     1                  
  **CD14+ monocyte**                                    786                                             426                        13                                 3.1   8     1.9    1     0.2   
  **CD19+ B cell (neg. sel.)**                          1027                                            619                        11                                 1.8   16    2.6    1     0.2   
  **CD34+ cell**                                        433                                             295                        7                                  2.4   2     0.7                
  **CD34+ hematopoietic stem cell**                     941                                             639                        6                                  0.9   3     0.5                
  **CD34+ T cell**                                      219                                             91                         4                                  4.4   4     4.4                
  **CD4+ T cell**                                       622                                             315                        10                                 3.2   6     1.9    1     0.3   
  **CD8+ T cell**                                       344                                             131                        4                                  3.1   1     0.8                
  **Central memory 1 CD4+ T cell**                      228                                             72                         1                                  1.4   3     4.2                
  **Central memory CD4+ T cell**                        220                                             79                         3                                  3.8   6     7.6                
  **Effector memory CD4+ T cell**                       154                                             47                         4                                  8.5   7     14.9               
  **Erythrocyte**                                       247                                             140                        8                                  5.7   9     6.4    1     0.7   
  **Granulocyte**                                       342                                             203                        3                                  1.5   2     1                  
  **Hematopoietic stem cell**                           1148                                            723                        11                                 1.5   3     0.4                
  **Lymphocyte**                                        348                                             255                        11                                 4.3   14    5.5    1     0.4   
  **Macrophage**                                        382                                             225                        11                                 4.9   14    6.2    2     0.9   
  **Monocyte**                                          147                                             91                         8                                  8.8   8     8.8    1     1.1   
  **Monocyte derived macrophage**                       430                                             266                        10                                 3.8   14    5.3    2     0.8   
  **Naive CD4+ T cell**                                 248                                             89                         3                                  3.4   1     1.1                
  **Primary bone marrow CD34+ stem cell**               398                                             199                        5                                  2.5   3     1.5    1     0.5   
  **Progenitor cell, hematopoietic stem cell**          440                                             207                        6                                  2.9   2     1                  
  **T cell**                                            532                                             284                        16                                 5.6   13    4.6    1     0.4   
  **T lymphocyte**                                      193                                             88                         5                                  5.7   5     5.7                
  **Bone marrow**                                       **CD138+ plasma cell**                          936                        526                                15    2.9   9      1.7   3     0.6
  **Immature-B cell**                                   212                                             87                         1                                  1.1                            
  **Mesenchymal stem cell**                             307                                             175                        4                                  2.3   1     0.6                
  **Mesenchymal stem cell BM-MSC**                      474                                             263                        4                                  1.5                            
  **Pre-B-I cell**                                      444                                             229                        4                                  1.7                            
  **Pre-B-II large cell**                               830                                             485                        3                                  0.6                            
  **Pre-B-II small cell**                               466                                             242                        3                                  1.2   1     0.4                
  **Primary bone marrow CD34- mesenchymal stem cell**   209                                             80                         3                                  3.8                            
  **Primary bone marrow CD34+ stem cell**               252                                             116                        10                                 8.6   3     2.6                
  **Connective tissue**                                 **Fibroblast**                                  305                        131                                4     3.1   3      2.3         
  **Esophagus**                                         **Esophageal epithelium**                       702                        399                                11    2.8   10     2.5   1     0.3
  **Eye**                                               **Trabecular meshwork**                         540                        319                                4     1.3                      
  **Trabecular meshwork cell**                          561                                             297                        6                                  2     1     0.3                
  **Kidney**                                            **Epithelium**                                  596                        346                                6     1.7   3      0.9         
  **Mesagnium**                                         **Mesangial cell**                              396                        169                                3     1.8                      
  **Ovary**                                             **Theca**                                       746                        393                                3     0.8                      
  **Palatine tonsil**                                   **CXCR5(-)ICOS(-/lo) CD4+ T cell**              196                        83                                 2     2.4                      
  **CXCR5(hi)ICOS(hi) CD4+ T cell**                     212                                             66                         4                                  6.1   4     6.1                
  **CXCR5(lo)ICOS(int) CD4+ T cell**                    174                                             55                         2                                  3.6   3     5.5                
  **Skin**                                              **Epidermis and dermis**                        650                        385                                12    3.1   10     2.6   1     0.3
  **Primary blood vessel endothelial cell**             314                                             138                        6                                  4.3   1     0.7    1     0.7   
  **Primary lymphatic endothelial cell**                348                                             152                        4                                  2.6   1     0.7                
  **Primary microvascular endothelial cell**            446                                             213                        6                                  2.8   1     0.5    1     0.5   
  **Skin (leg)**                                        **Epidermis and dermis**                        658                        378                                12    3.2   10     2.6         
  **Thymus**                                            **CD34+CD1a- thymocyte**                        334                        139                                1     0.7   1      0.7         
  **CD34+CD38- thymocyte**                              801                                             479                        3                                  0.6   1     0.2                
  **DP CD3- thymocyte**                                 319                                             170                        1                                  0.6                            
  **DP CD3+ thymocyte**                                 402                                             140                        1                                  0.7   2     1.4                
  **ISP CD4+ thymocyte**                                340                                             200                        1                                  0.5                            
  **SP CD4+ thymocyte**                                 346                                             121                        1                                  0.8   1     0.8                
  **SP CD8+ thymocyte**                                 270                                             90                         1                                  1.1                            
  **Thyrocyte**                                         406                                             218                        7                                  3.2   4     1.8                
  **Uterine tube**                                      **Primary uterine smooth muscle cell**          460                        227                                6     2.6   3      1.3         

A: asthma. D: dermatitis. R: rhinitis. Light blue background: the number of genes is significantly higher than random expectation (adjusted *P* \< 0.05). Dark blue background: the number of genes is significantly higher than random expectation (adjusted *P* \< 0.01). For clarity, zero values are represented as blank cells, and cell types without any disease-associated genes are not shown.

Cellular pathways {#sec019}
-----------------

The number of pathways in Reactome database was 519 after filtering, with an average pairwise overlap of 0.01%. Overall, 6,989 genes were associated to at least one pathway. On average, \~37% of genes on cell-type-specific networks were associated to at least one pathway. The fraction of pathway-associated genes present in each cell type is shown in [S4 Table](#pone.0224448.s006){ref-type="supplementary-material"}. The list of genes associated to each pathway in each cell-type-specific network is provided in [S5 Table](#pone.0224448.s007){ref-type="supplementary-material"}. The connectivity *C*^*c*^~*p*~ of the pathways is shown in [S6 Table](#pone.0224448.s008){ref-type="supplementary-material"}. As an example, [Fig 3](#pone.0224448.g003){ref-type="fig"} shows cellular pathway (*Regulation of TLR by endogenous ligand*) mapped onto a cell-type specific network (CD19+ B cell).

![Pathway *Toll Like Receptor 4 TLR4 Cascade* on the *CD19+ B cell* specific network.\
**(A)** Complete view of the largest component of the network. Pathway-associated genes and their interactions are shown in orange. **(B)** Zoom to the pathway-associated genes and their closest neighbors only. Pathway-associated genes and their connections are shown in orange. **(C)** Top-scoring asthma genes (see [Methods](#sec006){ref-type="sec"}) are shown with blue borders. **(D)** Top-scoring dermatitis genes are shown with blue borders. **(E)** Top-scoring rhinitis genes are shown with blue borders. The fraction of pathway genes within the top-scoring gene sets is only significant for dermatitis and rhinitis. **(F-H)** Distribution of random Perturbation Score (*PS*) for A, D and R, respectively. An arrow represents the real *PS*. Pathways whose *PS* is significantly larger than random expectation (*P* \< 0.05, panels G and H) are denoted as perturbed in the respective disease.](pone.0224448.g003){#pone.0224448.g003}

Quantification of cell-type-specific multimorbidity {#sec020}
---------------------------------------------------

The Multimorbidity Score (*MS*) quantitatively measured the multimorbidity between A, D and R specific to different cell types ([Table 3](#pone.0224448.t003){ref-type="table"}). [S2 Table](#pone.0224448.s004){ref-type="supplementary-material"} contains the number of top-scoring genes for each disease on each cell-type-specific network (\|*S*^*c*^~*d*~\|, see [Methods](#sec006){ref-type="sec"}). Of the 60 cell-type-specific networks, 12 were associated to a single disease and were not considered for further multimorbidity analysis. Inspection of [Table 3](#pone.0224448.t003){ref-type="table"} shows 14 cell types associated to ADR multimorbidity because their *MS* value is \> 0 for all combinations of the three diseases (the strength of the association given by the MS value, ranging from 0 to 1). The cell types include monocytes-macrophages, T cells and plasma cells, as well as skin endothelial cells and esophageal epithelial cells. These 14 cell types will be subject to scrutiny in the following sections. [S7 Table](#pone.0224448.s009){ref-type="supplementary-material"} provides a combined overview of the results of Tables [2](#pone.0224448.t002){ref-type="table"} and [3](#pone.0224448.t003){ref-type="table"}, containing the cell types with a significant number of A-, D- or R-associated genes as well as those cell types with nonzero *MS*.

10.1371/journal.pone.0224448.t003

###### Cell-type-specific multimorbidities between asthma, dermatitis and rhinitis.

![](pone.0224448.t003){#pone.0224448.t003g}

  tissue                                         cell type / line                                AD     AR     DR     ADR
  ---------------------------------------------- ----------------------------------------------- ------ ------ ------ ------
  **Adipose tissue from abdomen and thigh**      **Adipose-derived adult stem cells (ADASCs)**   0.35                 
  **Adipose tissue from abdomen**                **Adipose-derived adult stem cells (ADASCs)**   0.35   0.25   0.36   0.24
  **Aorta**                                      **Primary aortic smooth muscle cell**           0.29                 
  **Blood**                                      **721 B lymphoblasts**                          0.08                 
  **BDCA4+ dentritic cell**                      0.18                                                                 
  **CD14+ monocyte**                             0.77                                            0.71   0.83   0.70   
  **CD19+ B cell (neg. sel.)**                   0.17                                            0.33   0.21   0.09   
  **CD34+ T cell**                               0.12                                                                 
  **CD34+ cell**                                 0.65                                                                 
  **CD34+ hematopoietic stem cell**              0.20                                                                 
  **CD4+ T cell**                                0.58                                            0.50   0.58   0.31   
  **CD8+ T cell**                                0.11                                                                 
  **Central memory 1 CD4+ T cell**               0.57                                                                 
  **Central memory CD4+ T cell**                 0.33                                                                 
  **Effector memory CD4+ T cell**                0.36                                                                 
  **Erythrocyte**                                0.38                                            0.38   0.22   0.24   
  **Granulocyte**                                0.33                                                                 
  **Hematopoietic stem cell**                    0.19                                                                 
  **Lymphocyte**                                 0.42                                            0.33   0.37   0.24   
  **Macrophage**                                 0.17                                            0.29   0.24   0.11   
  **Monocyte**                                   0.38                                            0.50   0.33   0.30   
  **Monocyte derived macrophage**                0.15                                            0.24   0.21   0.10   
  **Naive CD4+ T cell**                          0.50                                                                 
  **Primary bone marrow CD34+ stem cell**                                                        0.45                 
  **Progenitor cell, hematopoietic stem cell**   0.22                                                                 
  **T cell**                                     0.48                                            0.15   0.16   0.11   
  **T lymphocyte**                               0.40                                                                 
  **Bone marrow**                                **CD138+ plasma cell**                          0.38   0.47   0.71   0.33
  **Pre-B-II small cell**                        0.07                                                                 
  **Primary bone marrow CD34+ stem cell**        0.29                                                                 
  **Connective tissue**                          **Fibroblast**                                  0.14                 
  **Esophagus**                                  **Esophageal epithelium**                       0.27   0.43   0.33   0.29
  **Kidney**                                     **Epithelium**                                  0.11                 
  **Palatine tonsil**                            **CXCR5(hi)ICOS(hi) CD4+ T cell**               0.50                 
  **CXCR5(lo)ICOS(int) CD4+ T cell**             0.40                                                                 
  **Skin (leg)**                                 **Epidermis and dermis**                        0.26                 
  **Skin**                                       **Epidermis and dermis**                        0.35   0.14   0.16   0.13
  **Primary blood vessel endothelial cell**      0.38                                            0.11   0.20          
  **Primary lymphatic endothelial cell**         0.12                                                                 
  **Primary microvascular endothelial cell**     0.50                                            0.50   1.00   0.60   
  **Thyroid**                                    **Thyrocyte**                                   0.54                 
  **Uterine tube**                               **Primary uterine smooth muscle cell**          0.11                 

The gradient of red correspond to the values of the Multimorbidity Score (MS, indicated within the cells; 0 ≤ MS ≤ 1). Empty cells have a MS = 0.

Cell-type-specific multimorbidity mechanisms {#sec021}
--------------------------------------------

[Table 4](#pone.0224448.t004){ref-type="table"} shows the pathways identified as candidate mechanisms for multimorbidity in the 14 cell types where *MS* for ADR is \>0 ([Table 3](#pone.0224448.t003){ref-type="table"}), where pathways in the *Cytokine signaling in immune system* category roughly correspond to the pathways activated in the type-2 asthmatic response (particularly, *IL4* and *IL13* signaling \[[@pone.0224448.ref071], [@pone.0224448.ref072]\]). [S8 Table](#pone.0224448.s010){ref-type="supplementary-material"} shows candidate mechanisms in all other cell types (which are restricted to AD multimorbidity except for one pathway in primary bone marrow CD34+ stem cells, associated to AR multimorbidity). It is noteworthy that some cell types do not present any significant mechanism for multimorbidity despite being associated to multimorbidity in [Table 3](#pone.0224448.t003){ref-type="table"} (namely, epidermis/dermis, and primary microvascular endothelial cells, not associated to any pathway). Other cell types are strongly associated to ADR multimorbidity while not being associated to any mechanism for ADR multimorbidity. This is the case of CD14+ monocytes, for which only a mechanism mediation AD multimorbidity (*NOD1/2 signaling pathway*) was found. The reason for these observations is that, on average, only \~37% of genes in a given cell type are annotated to a least one pathway ([S4 Table](#pone.0224448.s006){ref-type="supplementary-material"}). Thus, a large number of non-annotated genes might be still contributing to multimorbidity. The cellular pathways perturbed in each individual disease and cell type (i.e *PS*^*c*^~*pd*~ significant at *P* \< 0.05, see [Methods](#sec006){ref-type="sec"}) are provided in [S9 Table](#pone.0224448.s011){ref-type="supplementary-material"}.

10.1371/journal.pone.0224448.t004

###### Cellular pathways associated to multimorbidity between asthma, dermatitis and rhinitis.

![](pone.0224448.t004){#pone.0224448.t004g}

  category                                              pathway                                         Adipose tissue from abdomen   Blood   Bone marrow   Esophagus   Skin                                            
  ----------------------------------------------------- ----------------------------------------------- ----------------------------- ------- ------------- ----------- ------ ----- ---- ---- ---- ----- ----- ---- -- --
  **Metabolism of carbohydrates**                       **Heparan sulfate heparin HS-GAG metabolism**                                         AR                                                                        
  **Chondroitin sulfate dermatan sulfate metabolism**                                                                                 AR                                                                                
  **Apoptosis**                                         **Ligand-dependent caspase activation**                                                             AD                                      ADR                 
  **Signaling by GPCR**                                 **G-protein beta gamma signalling**                                                                                    ADR                                      
  **Death receptor signalling**                         **TNFR1-induced proapoptotic signaling**                                                            AD                                                          
  **Cytokine signaling in immune system**               **Interleukin-1 signaling**                                                           ADR                                                   AD          AR      
  **Other interleukin signaling**                                                                                                                                       ADR                                             
  **Interleukin-10 signaling**                          AD                                                                            ADR     DR                        AD     AD              AD                       
  **Interleukin-4 and 13 signaling**                    AD                                                                                                              AD                     AD                       
  **Adaptive immune system**                            **Antigen processing-Cross presentation**                                                                       AR                                ADR           
  **Innate immune system**                              **Toll Like Receptor 4 TLR4 Cascade**                                                 DR            AD          AR                AR              ADR           
  **Toll Like Receptor 9 TLR9 Cascade**                                                                                               ADR                                                                               
  **Toll Like Receptor 10 TLR10 Cascade**                                                                                             DR                                                                                
  **Toll Like Receptor 3 TLR3 Cascade**                                                                                               DR                                                                                
  **Toll Like Receptor 2 TLR2 Cascade**                                                                                               ADR                   AR                            AR        ADR                 
  **Regulation of TLR by endogenous ligand**                                                                                          DR                    AR                       AR        DR   AD                  
  **NOD1/2 Signaling Pathway**                                                                          AD                                                                                                              

Red cells: multimorbidity between A and D. Orange cells: multimorbidity between A and R. Light blue cells: multimorbidity between D and R. Dark blue cells: multimorbidity between A, D and R. Only cell types with MS \> 0 for multimorbidity between A, D and R are shown.

Candidate multimorbidity genes {#sec022}
------------------------------

[Table 5](#pone.0224448.t005){ref-type="table"} shows the 30 top-scoring candidate genes for multimorbidity (and [S10 Table](#pone.0224448.s012){ref-type="supplementary-material"} contains the full collection of candidate genes). The score assigned to multimorbidity (columns AD, AR, DR, ADR in [Table 5](#pone.0224448.t005){ref-type="table"} and [S10 Table](#pone.0224448.s012){ref-type="supplementary-material"}) can be read as the importance of the gene as mediator for multimorbidity. As expected, many of the top-scoring candidates are associated to immune system pathways. It is noteworthy that some genes may be associated to pathways which are, in fact, not characterized as multimorbidity mechanisms. For instance, [Table 5](#pone.0224448.t005){ref-type="table"} shows *IL13* gene as a strong ADR multimorbidity candidate in esophageal epithelium. This gene is annotated as belonging to the *Interleukin-10 signaling* an *Interleukin-4 and 13 signaling* pathways. However, neither pathway was characterized as a mechanism of multimorbidity for esophageal epithelium in [Table 4](#pone.0224448.t004){ref-type="table"}, because their perturbation score *PS*^*T*^~*pd*~ did not reach statistical significance. Genes in [Table 5](#pone.0224448.t005){ref-type="table"} show a higher score, on average, for AR than for AD multimorbidity (*P* = 0.01482; paired Wilcoxon-Mann-Whitney test), implying a more closely-knit biological mechanism for AR than for AD multimorbidity. The same was observed for AD vs DR (*P* = 1.02·10^−3^; paired Wilcoxon-Mann-Whitney test) but not for AR vs DR. This observation was also true when comparing scores of the whole set of predicted genes in [S10 Table](#pone.0224448.s012){ref-type="supplementary-material"}. Comparisons are shown in [S11 Table](#pone.0224448.s013){ref-type="supplementary-material"}. Genes which are not known be associated to any of the diseases under study (i.e. they are not present in [Table 1](#pone.0224448.t001){ref-type="table"}) but were characterized as candidates for multimorbidity are particularly interesting candidates for experimental characterization. There are 100 genes of this kind, and 21 of them are candidates for ADR multimorbidity. [Table 6](#pone.0224448.t006){ref-type="table"} shows the 30 top-scoring ones.

10.1371/journal.pone.0224448.t005

###### Candidate genes associated to multimorbidity between A, D and R.

![](pone.0224448.t005){#pone.0224448.t005g}

  --------------------------------- ----------------------------------------------- --------------- -------- -------- -------- --------- ------- ------- ------- ------------------------------------------- ----------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ------------------------------------------- --------------------------------------- ------------------------------------ -------------------------------------------- ------------------------------------- -------------------------------------
  **tissue**                        **cell type**                                   **gene**        **AD**   **AR**   **DR**   **ADR**   **A**   **D**   **R**   **DAP12 signaling**                         **Interleukin-1 signaling**   **Interleukin-17 signaling**            **Other interleukin signaling**         **Interleukin-2 signaling**             **Interleukin-3, 5 and GM-CSF signaling**   **Interleukin-6 family signaling**      **Interleukin-10 signaling**         **Interleukin-4 and 13 signaling**           **Interleukin-20 family signaling**   **Interferon alpha beta signaling**
  **Skin**                          **Primary microvascular endothelial cell**      ***IL1RL1***    8.09     8.09     10.25    8.81      ●               ●                                                                                                                         ●                                                                                                                                                                                                                                                                                           
  **Skin**                          **Primary microvascular endothelial cell**      ***IL33***      8.09     8.09     10.25    8.81      ●       ●                                                                                                                                 ●                                                                                                                                                                                                                                                                                           
  **Esophagus**                     **Esophageal epithelium**                       ***IL13***      5.62     9.89     9.16     8.22      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Skin**                          **Epidermis and dermis**                        ***PLA2G7***    4.71     9.68     9.29     7.90      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Adipose tissue from abdomen**   **Adipose-derived adult stem cells (ADASCs)**   ***IL33***      5.53     8.72     8.95     7.73      ●       ●                                                                                                                                 ●                                                                                                                                                                                                                                                                                           
  **Adipose tissue from abdomen**   **Adipose-derived adult stem cells (ADASCs)**   ***IL1RL1***    4.77     9.31     8.07     7.38      ●               ●                                                                                                                         ●                                                                                                                                                                                                                                                                                           
  **Blood**                         **CD14+ monocyte**                              ***IL13***      5.78     7.21     7.67     6.88      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Esophagus**                     **Esophageal epithelium**                       ***IL33***      6.63     7.32     6.48     6.81      ●       ●                                                                                                                                 ●                                                                                                                                                                                                                                                                                           
  **Bone marrow**                   **CD138+ plasma cell**                          ***PLA2G7***    5.67     6.84     5.89     6.13      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD4+ T cell**                                 ***IL13***      4.95     6.53     6.79     6.09      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Bone marrow**                   **CD138+ plasma cell**                          ***IL13***      5.16     5.92     6.41     5.83      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Bone marrow**                   **CD138+ plasma cell**                          ***TLR1***      3.96     7.07     5.51     5.51      ●               ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Bone marrow**                   **CD138+ plasma cell**                          ***CD14***      6.07     4.76     5.48     5.44      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Esophagus**                     **Esophageal epithelium**                       ***IL22RA1***   3.45     6.63     6.20     5.43                                                                                                                                                                                                                                                                                                                                                                                                      ●                                     
  **Blood**                         **CD14+ monocyte**                              ***IL18R1***    6.19     4.83     5.21     5.41      ●       ●                                                                                                                                 ●                                                                                                                                                                                                                                                                                           
  **Skin**                          **Epidermis and dermis**                        ***BCHE***      2.37     6.80     6.66     5.28                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Blood**                         **CD14+ monocyte**                              ***IL5***       5.91     4.39     4.92     5.07      ●       ●               ●                                                                         ●                                                                               ●                                       ●                                                                                                                                                                                                           
  **Blood**                         **CD19+ B cell (neg. sel.)**                    ***IRAK3***     5.33     4.23     4.10     4.55      ●       ●                                                           ●                                                                                                                                                                                                                                                                                                                                                                 
  **Esophagus**                     **Esophageal epithelium**                       ***IL20RA***    2.92     5.24     4.84     4.33                                                                                                                                                                                                                                                                                                                                                                                                      ●                                     
  **Blood**                         **CD14+ monocyte**                              ***ARG1***      4.28     5.17     3.33     4.26      ●                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***IL18RAP***   4.46     3.10     5.21     4.26              ●                                                                                                                                 ●                                                                                                                                                                                                                                                                                           
  **Blood**                         **CD14+ monocyte**                              ***IL11***      3.25     4.32     4.75     4.10                                                                                                                                                                                                                                                                            ●                                                                                                                                                               
  **Blood**                         **CD14+ monocyte**                              ***IFNA8***     3.25     4.32     4.75     4.10                                                                                                                                                                                                                                                                                                                                                                                                                                            ●
  **Blood**                         **CD19+ B cell (neg. sel.)**                    ***CD14***      5.05     3.57     3.48     4.03      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Bone marrow**                   **CD138+ plasma cell**                          ***RNASE3***    4.00     4.90     2.94     3.95      ●                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***FOXP3***     4.17     2.68     4.95     3.93              ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                         **Monocyte derived macrophage**                 ***IL13***      3.51     4.03     3.81     3.78      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Blood**                         **Lymphocyte**                                  ***IL13***      3.34     3.98     3.78     3.70      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Blood**                         **Macrophage**                                  ***IL13***      3.30     3.85     3.71     3.62      ●       ●       ●                                                                                                                                                                                                                                                                                             ●                                    ●                                                                                  
  **Blood**                         **CD14+ monocyte**                              ***IL9***       2.84     3.77     4.06     3.56                                                                                                                                                ●                                                                                                                                                                                                                                                                                           
  **tissue**                        **cell type**                                   **gene**        **AD**   **AR**   **DR**   **ADR**   **A**   **D**   **R**   **Antigen processing-Cross presentation**   **Defensins**                 **Toll Like Receptor 4 TLR4 Cascade**   **Toll Like Receptor 9 TLR9 Cascade**   **Toll Like Receptor 3 TLR3 Cascade**   **Toll Like Receptor 7 8 TLR7 8 Cascade**   **Toll Like Receptor 2 TLR2 Cascade**   **FCERI mediated MAPK activation**   **Regulation of TLR by endogenous ligand**   **TRAF6 mediated IRF7 activation**    
  **Skin**                          **Primary microvascular endothelial cell**      ***IL1RL1***    8.09     8.09     10.25    8.81      ●               ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Skin**                          **Primary microvascular endothelial cell**      ***IL33***      8.09     8.09     10.25    8.81      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Esophagus**                     **Esophageal epithelium**                       ***IL13***      5.62     9.89     9.16     8.22      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Skin**                          **Epidermis and dermis**                        ***PLA2G7***    4.71     9.68     9.29     7.90      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Adipose tissue from abdomen**   **Adipose-derived adult stem cells (ADASCs)**   ***IL33***      5.53     8.72     8.95     7.73      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Adipose tissue from abdomen**   **Adipose-derived adult stem cells (ADASCs)**   ***IL1RL1***    4.77     9.31     8.07     7.38      ●               ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***IL13***      5.78     7.21     7.67     6.88      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Esophagus**                     **Esophageal epithelium**                       ***IL33***      6.63     7.32     6.48     6.81      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Bone marrow**                   **CD138+ plasma cell**                          ***PLA2G7***    5.67     6.84     5.89     6.13      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD4+ T cell**                                 ***IL13***      4.95     6.53     6.79     6.09      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Bone marrow**                   **CD138+ plasma cell**                          ***IL13***      5.16     5.92     6.41     5.83      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Bone marrow**                   **CD138+ plasma cell**                          ***TLR1***      3.96     7.07     5.51     5.51      ●               ●       ●                                           ●                             ●                                                                                                                                                                   ●                                                                            ●                                                                                  
  **Bone marrow**                   **CD138+ plasma cell**                          ***CD14***      6.07     4.76     5.48     5.44      ●       ●               ●                                                                         ●                                       ●                                       ●                                       ●                                           ●                                                                            ●                                                                                  
  **Esophagus**                     **Esophageal epithelium**                       ***IL22RA1***   3.45     6.63     6.20     5.43                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Blood**                         **CD14+ monocyte**                              ***IL18R1***    6.19     4.83     5.21     5.41      ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Skin**                          **Epidermis and dermis**                        ***BCHE***      2.37     6.80     6.66     5.28                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Blood**                         **CD14+ monocyte**                              ***IL5***       5.91     4.39     4.92     5.07      ●       ●                                                                                                                                                                                                                                                                                                     ●                                                                                                                       
  **Blood**                         **CD19+ B cell (neg. sel.)**                    ***IRAK3***     5.33     4.23     4.10     4.55      ●       ●                                                                                         ●                                                                                                                                                                   ●                                                                                                                                                               
  **Esophagus**                     **Esophageal epithelium**                       ***IL20RA***    2.92     5.24     4.84     4.33                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Blood**                         **CD14+ monocyte**                              ***ARG1***      4.28     5.17     3.33     4.26      ●                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***IL18RAP***   4.46     3.10     5.21     4.26              ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                         **CD14+ monocyte**                              ***IL11***      3.25     4.32     4.75     4.10                                                                                                                                                                                                                                                                                                                                                                                                                                            
  **Blood**                         **CD14+ monocyte**                              ***IFNA8***     3.25     4.32     4.75     4.10                                                                                                                                                                                                                                                                                                                                                                                                      ●                                     
  **Blood**                         **CD19+ B cell (neg. sel.)**                    ***CD14***      5.05     3.57     3.48     4.03      ●       ●               ●                                                                         ●                                       ●                                       ●                                       ●                                           ●                                                                            ●                                                                                  
  **Bone marrow**                   **CD138+ plasma cell**                          ***RNASE3***    4.00     4.90     2.94     3.95      ●                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***FOXP3***     4.17     2.68     4.95     3.93              ●                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                         **Monocyte derived macrophage**                 ***IL13***      3.51     4.03     3.81     3.78      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **Lymphocyte**                                  ***IL13***      3.34     3.98     3.78     3.70      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **Macrophage**                                  ***IL13***      3.30     3.85     3.71     3.62      ●       ●       ●                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Blood**                         **CD14+ monocyte**                              ***IL9***       2.84     3.77     4.06     3.56                                                                                                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------- ----------------------------------------------- --------------- -------- -------- -------- --------- ------- ------- ------- ------------------------------------------- ----------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ------------------------------------------- --------------------------------------- ------------------------------------ -------------------------------------------- ------------------------------------- -------------------------------------

Column AD (red background): score of the gene in multimorbidity between A and D. Column AR (orange background): score of the gene in multimorbidity between A and R. Column DR (light blue background): score of the gene in multimorbidity between D and R. Column ADR (dark blue background): multimorbidity between A, D and R. Scores within columns AD to ADR are the average z-scores for each gene in each cell type for the corresponding diseases (see [Methods](#sec006){ref-type="sec"}). Column A: a dot indicates that the gene is known to be associated to asthma. Column D: a dot indicates that the gene is known to be associated to dermatitis. Column R: a dot indicates that the gene is known to be associated to rhinitis. Columns labeled after pathways: a dot indicates that the gene is known to be associated to the corresponding pathway (for brevity, only pathways related to the immune system are shown). Genes in the table are ranked according to their average score across the AD, AR, DR and ADR columns, and only the 30 top-scoring genes are shown.

10.1371/journal.pone.0224448.t006

###### Candidate genes associated to multimorbidity between A, D and R, and not associated to any of the diseases.

![](pone.0224448.t006){#pone.0224448.t006g}

  tissue                                      cell type                                       gene            AD     AR     DR     ADR    Interleukin-1 signaling   Interleukin-12 family signaling   Other interleukin signaling   Interleukin-6 family signaling   Interleukin-10 signaling   Interleukin-4 and 13 signaling   Interleukin-20 family signaling   Interferon alpha beta signaling   Antigen processing-Cross presentation   ZBP1DAI mediated induction of type I IFNs   Toll Like Receptor 4 TLR4 Cascade   Toll Like Receptor 2 TLR2 Cascade   Regulation of innate immune responses to cytosolic DNA   Regulation of TLR by endogenous ligand   Inflammasomes   TRAF6 mediated IRF7 activation   Negative regulators of RIG-I MDA5 signaling
  ------------------------------------------- ----------------------------------------------- --------------- ------ ------ ------ ------ ------------------------- --------------------------------- ----------------------------- -------------------------------- -------------------------- -------------------------------- --------------------------------- --------------------------------- --------------------------------------- ------------------------------------------- ----------------------------------- ----------------------------------- -------------------------------------------------------- ---------------------------------------- --------------- -------------------------------- ---------------------------------------------
  **Esophagus**                               **Esophageal epithelium**                       ***IL22RA1***   3.45   6.63   6.20   5.43                                                                                                                                                                                          ●                                                                                                                                                                                                                                                                                                                                                                                  
  **Skin**                                    **Epidermis and dermis**                        ***BCHE***      2.37   6.80   6.66   5.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **CD19+ B cell (neg. sel.)**                    ***NCAN***             5.93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Blood**                                   **CD19+ B cell (neg. sel.)**                    ***CSPG5***            5.93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Esophagus**                               **Esophageal epithelium**                       ***IL20RA***    2.92   5.24   4.84   4.33                                                                                                                                                                                          ●                                                                                                                                                                                                                                                                                                                                                                                  
  **Blood**                                   **CD14+ monocyte**                              ***IL11***      3.25   4.32   4.75   4.10                                                                                             ●                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Blood**                                   **CD14+ monocyte**                              ***IFNA8***     3.25   4.32   4.75   4.10                                                                                                                                                                                                                            ●                                                                                                                                                                                                                                                                                                               ●                                
  **Blood**                                   **CD14+ monocyte**                              ***IL9***       2.84   3.77   4.06   3.56                                                               ●                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Bone marrow**                             **CD138+ plasma cell**                          ***CD180***     3.17   3.60   3.88   3.55                                                                                                                                                                                                                                                                                                                                                  ●                                                                                                                                                                                                                          
  **Bone marrow**                             **CD138+ plasma cell**                          ***RNASE2***    2.78   4.03   3.76   3.52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Bone marrow**                             **CD138+ plasma cell**                          ***EPX***       2.78   4.03   3.76   3.52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **CD14+ monocyte**                              ***PRLR***      2.90   3.66   3.97   3.51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **Granulocyte**                                 ***NLRP3***     4.67                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ●                                                
  **Blood**                                   **CD19+ B cell (neg. sel.)**                    ***VCAN***             3.97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Blood**                                   **CD4+ T cell**                                 ***IL22***                    3.63                                                                                                                                                                                                 ●                                                                                                                                                                                                                                                                                                                                                                                  
  **Blood**                                   **CD14+ monocyte**                              ***IL23A***     2.32   2.86   3.05   2.75                             ●                                                                                                                           ●                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Blood**                                   **CD4+ T cell**                                 ***IL11RA***                  3.35                                                                                                    ●                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Blood**                                   **CD4+ T cell**                                 ***PRLR***                    3.35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Bone marrow**                             **CD138+ plasma cell**                          ***TLR6***      2.13   2.86   3.13   2.71                                                                                                                                                                                                                                                              ●                                                                                   ●                                   ●                                                                                            ●                                                                                         
  **Blood**                                   **CD14+ monocyte**                              ***HPCAL4***    2.35   2.95   2.64   2.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **CD14+ monocyte**                              ***CHP2***      2.35   2.95   2.64   2.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **CD14+ monocyte**                              ***CIB2***      2.35   2.95   2.64   2.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Blood**                                   **CD14+ monocyte**                              ***OCM2***      2.35   2.95   2.64   2.64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Bone marrow**                             **CD138+ plasma cell**                          ***LBP***       2.26   2.56   2.62   2.48                                                                                                                                                         ●                                                                                                                                                                                        ●                                                                                                                                ●                                                                                         
  **Adipose tissue from abdomen and thigh**   **Adipose-derived adult stem cells (ADASCs)**   ***MTMR8***     3.69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Esophagus**                               **Esophageal epithelium**                       ***IL18***             2.98                 ●                                                           ●                                                              ●                          ●                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Blood**                                   **CD4+ T cell**                                 ***CHP2***             2.91                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Blood**                                   **CD4+ T cell**                                 ***ZBP1***      2.54   2.11   2.50   2.38                                                                                                                                                                                                                                                                                                      ●                                                                                                                   ●                                                                                                                                                  
  **Blood**                                   **CD4+ T cell**                                 ***RNF216***    2.54   2.11   2.50   2.38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ●
  **Skin**                                    **Primary blood vessel endothelial cell**       ***CCNA1***                   2.77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

Column contents and background colors are as in [Table 5](#pone.0224448.t005){ref-type="table"}. Genes in the table are ranked according to their average score across the AD, AR, DR and ADR columns, and only the 30 top-scoring genes are shown.

Discussion {#sec023}
==========

In this study, we have performed an interactome-based analysis of expression data to characterize specific mechanisms for multimorbidity between asthma (A), dermatitis (D) and rhinitis (R) in distinct 14 non-eosinophilic cell types and 15 tissues. We observed differential roles for cytokine signaling, particularly associated with type 2 inflammation, TLR-mediated signaling and metabolic pathways for multimorbidities across distinct cell types. Furthermore, we also identified individual genes potentially associated to multimorbidity mechanisms.

Strengths {#sec024}
---------

Interactome-based computational analysis provide a global view of the increasing complexity of disease-gene association data, and the relationships among diseases, genes and functions \[[@pone.0224448.ref073]\]. By employing an expression compendium that incorporates information on multiple heterogeneous gene expression experiments, we were able to identify cell-type-specific mechanisms that underlie the multimorbidity between A, D and R, focusing on 14 cell types that are emerging as major components in these complex diseases in 15 distinct tissues. Although eosinophils are an important cell type in A \[[@pone.0224448.ref030], [@pone.0224448.ref074]\], we focused on other important yet no so well-studied cell types in connection to ADR multimorbidity.

Our approach characterizes the mechanisms of multimorbidity not only by analyzing the contributions of individual genes, but also their interrelationship and their connectivity to other genes within the interactome. This is relevant because molecular causes of multimorbidity are not restricted to shared genes, but involve a cascade of common perturbed cellular mechanisms without which the whole mechanisms of multimorbidity cannot be properly characterized. Although the statistical analysis of the overlap between sets of genes has been widely employed to uncover disease-disease and disease-pathway associations, the limited knowledge of disease-associated genes and lack of annotation data have hampered its results \[[@pone.0224448.ref075], [@pone.0224448.ref076]\]. More recent approaches incorporating interactome-derived data provided a substantial improvement to characterize multimorbidity \[[@pone.0224448.ref020], [@pone.0224448.ref065], [@pone.0224448.ref076], [@pone.0224448.ref077]\]. Our approach can detect multimorbidity even if no shared genes are involved by identifying the cell-type-specific mechanisms associated to multimorbidity. In this respect, and because cellular pathways represent a curated set of gene functions which may be only partially present in some cell types, our method allows not only to statistically quantify if a pathway can be considered as a specific multimorbidity mechanism in a cell type, but also the discovery of particular genes involved in the multimorbidity process. Finally, our method is fully scalable approach, making it possible to study and characterize the etiology critical for multimorbidity between large groups of diseases. The findings of this *in silico* study are hypothesis-generating and are intended to guide new experiments on cell-type-specific allergic multimorbidity. Consequently, they should be confirmed by proper mechanistic and genetic studies.

Weaknesses {#sec025}
----------

As usual in differential expression studies, we are considering the gene expression level as a proxy for the gene activity. However, these two characteristics do not always match. For instance, a gene can be significantly over-expressed in a certain tissue or cell type and yet, at the same time, its product can be rendered inactive through a post-translational modification (e.g. phosphorylation). Our methodology does not capture those cases. Similarly, the time-dependent gene expression patterns are not captured in our study, which only considers an interactome static in time.

Lack of data availability also limited our analysis. Eosinophils are not a part of the expression compendium used in this study. However, to the best of our knowledge, no cell-type- or tissue-wide expression compendium resolving eosinophils as an individual cell type exists. This is why we chose to focus our attention in other cell types, important yet no so well-studied in connection to ADR multimorbidity. Furthermore, our dataset reflects only expression levels in healthy individuals because no cell-type-wide expression compendium in subjects with ADR multimorbidity exists.

Another limitation of our study is data completeness. The intersection of expression and interactome data sources yields a low coverage of the complete genome. Although this is a common limitation (and authors have argued that the current coverage of the human interactome does not limit its successful application to the investigation of disease mechanisms \[[@pone.0224448.ref005], [@pone.0224448.ref016]\]), some data loss is unavoidable: for instance, a protein such as filaggrin (*FLG*), commonly associated to multimorbidity between A and D \[[@pone.0224448.ref078]\], was not present in our expression dataset and could not be incorporated to the study. Also, our expression dataset contains data primarily from adult subjects. Thus, it is unclear if our results can be generalized to other age groups like young children or elderly people. However, we believe that gain in knowledge largely compensates these limitations.

As for disease-gene associations, we are including gene-disease associations partially derived from GWAS studies, whose reliability has been questioned \[[@pone.0224448.ref079]--[@pone.0224448.ref081]\]. Additionally, the current human interactome is highly biased toward highly studied genes (a category that includes many disease-associated genes), representing only a very small densely connected fraction of the full interactome \[[@pone.0224448.ref082]--[@pone.0224448.ref086]\]. This bias might be larger than expected and may have an impact on the biological conclusions extracted from the studies of the interactome \[[@pone.0224448.ref087]\]. However, non-biased interactomes have a much lower coverage, which makes them unsuitable for some topology-based studies \[[@pone.0224448.ref087]\]. We tried to address this effect by building null models which take into account the degree of the original genes. It should be also noted that there are numerous factors, other than genetic ones, that determine multimorbidity, some of which are environmental, lifestyle-related or treatment-induced. Finally, different mutations on the same gene can have different pathological effects on its gene products \[[@pone.0224448.ref088]\]. We considered all disease-associated mutations to have an effect on gene activity that, in turn, has a molecular impact on the interactome.

Quantification of cell-type-specific multimorbidity {#sec026}
---------------------------------------------------

The *MS* measure treats multimorbidity symmetrically with respect to the diseases being compared, meaning that it numerically reflects the mutual influence that the manifestation of one disease exerts over the other disease in a cell type. It can be interpreted as a measure of the degree to which a multimorbidity is present and specific to a certain cell type (regardless the fact that systemic mechanisms may be playing a role in multimorbidity as well, a case which is not captured by our method). Lower *MS* values imply that the specific mechanisms of the diseases are largely detached from each other in the corresponding cell type: the perturbation caused by the manifestation of one disease *d1* will be less likely to travel throughout the network and perturb the mechanisms that give rise to disease *d2*. At *MS* = 0 there is no multimorbidity between the diseases in the corresponding cell type (although multimorbidity may be present as a more systemic process). At *MS* = 1, the mechanisms of both diseases are identical in that cell type. We find an example of this in the primary microvascular endothelial cells, where *MS* = 1 for the DR multimorbidity. The implication of this is that not only the gene sets associated to D and R are identical in this cell type, but also that the gene sets influenced (or perturbed) by the malfunction of those genes are also identical, thus rendering both diseases the same disease in mechanistic terms for this cell type. Our methodology identifies cell-type-specific interactomes that are not exclusive of a single cell type: some parts of the interactome can be shared by more two or more (usually related) cell types.

*MS* revealed that all cell types with a significant number of disease-associated genes in at least one disease also display some degree of multimorbidity. For instance, genes associated to A and D are significantly associated to the monocyte cell-type-specific network ([Table 2](#pone.0224448.t002){ref-type="table"}), which also displays a *MS* \> 0 across all multimorbidities (AD, AR, DR, ADR; [Table 3](#pone.0224448.t003){ref-type="table"}). The reverse, however, is not necessarily true: primary microvascular endothelial cells displayed high *MS* values despite not showing any significant gene association. The reason lies in the use of interactome data, which takes into account the interconnectivity amongst genes as well as their number, allowing for the identification of multimorbidities that would go unnoticed in a standard association analysis. In this line, it is also of note that a significant number of disease-associated genes in a cell type does not necessarily imply a stronger *MS*. For instance, macrophages and monocyte-derived macrophages have a significant number of disease-associated genes for A and D, and yet their *MS* value for AD multimorbidity are 0.17 and 0.15, respectively. As another example, CD14+ T cells show large *MS* values for all multimorbidities despite the fact that no statistical association was found neither with D- nor with R-associated genes in this cell type.

Cell-type-specific multimorbidity mechanisms {#sec027}
--------------------------------------------

Cytokine signaling, critical to the induction of the type 2 response, seems to be the main mechanism behind AD multimorbidity, and it is present in a number of distinct cell types, blood-related or not ([Table 4](#pone.0224448.t004){ref-type="table"}, [S8 Table](#pone.0224448.s010){ref-type="supplementary-material"}). *IL4* and *IL13* have long been known to be amongst the cytokines secreted by Th2 cells in response to allergen-induced IgE synthesis in A, and the existence of an underlying *IL4*- and *IL13*-mediated pathomechanism for this multimorbidity has been suggested by a number of observations, for instance the response to similar treatments (e.g. dupilumab, a human monoclonal antibody that inhibits this type of signaling) \[[@pone.0224448.ref003]\]. *IL10*-associated signaling, a regulator of other proinflammatory cytokines \[[@pone.0224448.ref089]\], was also found as a contributing mechanism for AD multimorbidity across many cell types, as was *IL1*-associated signaling. *IL1* is a known inflammatory marker associated to D and bronchial A \[[@pone.0224448.ref090]\], amongst other diseases with inflammatory components. Interestingly, a role for *IL1* as a mediator in multimorbidities has already been hinted, as *IL1* blocking therapies have proven effective against conditions encountered as comorbidities in patients with rheumatic diseases \[[@pone.0224448.ref091], [@pone.0224448.ref092]\]. We have to point out, however, that the definition of a pathway (as a functionally annotated gene set) should be taken into account when analyzing those results. For instance, the pathway *Antigen Processing and Cross-Presentation* is associated to AR multimorbidity in erythrocytes ([Table 4](#pone.0224448.t004){ref-type="table"}). This contradicts evidence on MHC presence in human nonnucleated cells \[[@pone.0224448.ref093]\] because of the definition of the pathway in Reactome database, that includes genes also annotated in TLR-mediated pathways.

On the other hand, innate immune response mediated by toll-like receptors (TLRs) seems to be the key mechanism for multimorbidities implicating R. The TLR family of genes is important in barrier homeostasis and in the activation of the innate immune system \[[@pone.0224448.ref094]\], and there are evidences of its involvement in R \[[@pone.0224448.ref095]--[@pone.0224448.ref097]\]. Although the link between A and R is well established (the \"United Airways\" concept \[[@pone.0224448.ref098], [@pone.0224448.ref099]\]), there is limited knowledge about the mechanistic interplay between A and R \[[@pone.0224448.ref100], [@pone.0224448.ref101]\]. AR multimorbidity seems also largely restricted to a few blood-related cell types: CD19+ B cells, monocytes and erythrocytes. Genetic studies have linked the *TLR6-TLR1* locus to a role in the development of R \[[@pone.0224448.ref102]\], and changes in *TLR1* have been reported in asthmatic patients \[[@pone.0224448.ref017], [@pone.0224448.ref103]\], but no direct association between A and R is known. Similarly, changes in *TLR2* and *TLR4* expression are known to disturb the skin barrier in D \[[@pone.0224448.ref104]\]. According to our observations, *TLR4*-mediated cascade might play an important role in R-associated multimorbidities in blood-related cell types.

Esophageal epithelium cells seem to be also associated to AR multimorbidity by means of *IL1* signaling pathway and genes such as *IL-13* and *IL-33*. It is known that chronic eosinophilic inflammation of the esophagus is associated with tissue remodeling and fibrosis that shares many traits with A \[[@pone.0224448.ref105], [@pone.0224448.ref106]\]. Patients with eosinophilic esophagitis often present multimorbid conditions that include A and D \[[@pone.0224448.ref107]\]. It is also noteworthy the role of metabolism of proteoglycans in CD19+ B cells for this multimorbidity. In this sense, our results indicate that structurally similar proteoglycans neurocan (*NCAN*) and versican (*VCAN*) are related to this mechanism. Although no evidence linking these two genes to A or R is known, *VCAN* encodes an extracellular matrix protein that has been associated with A in murine models and with bronchiolitis in humans \[[@pone.0224448.ref108], [@pone.0224448.ref109]\].

We observed that cells of the skin epidermis/dermis, and primary microvascular endothelial cells were not significantly associated to any pathway. A number of reasons explain this observation: first, as already noted in the *Results* section, annotated pathways only cover approximately one-third of all genes in our cell-type-specific networks, leaving room for yet-unannotated mechanisms to play a critical role in multimorbidity. Second, our approach identifies *significantly* perturbed pathways, implying that some pathways may be perturbed without reaching the statistical significance cutoff of α = 0.05. Finally, our study only reflects cell-type-specific mechanisms, not excluding the existence of systemic mechanisms that may have relevant impact in a number of cell types. The fact that no pathway was characterized for these cell types, however, does not preclude the existence of individual candidate genes which might be playing a role in multimorbidity in them (see next section).

Cell-type-specific candidate genes {#sec028}
----------------------------------

We identified a number of individual genes as potentially associated to multimorbidity (Tables [5](#pone.0224448.t005){ref-type="table"} and [6](#pone.0224448.t006){ref-type="table"}; [S10 Table](#pone.0224448.s012){ref-type="supplementary-material"}). The identification of candidate genes complements the characterization of mechanisms of multimorbidity based on pathway annotation. For instance, interleukin 1 receptor-like 1 (*IL1RL1*) is amongst the top-scoring candidates for ADR multimorbidity in primary microvascular endothelial skin-derived cells, yet it is not associated to any pathway in this cell type (and, thus, its contribution would have been lost had we focused solely on pathway-annotated multimorbidity mechanisms). A candidate gene in a particular cell type may belong to a pathway not identified as a mechanism in that cell type. This is the case, for example, of the *IL13* gene, a high-scoring candidate gene in esophageal epithelium for ADR multimorbidity. This gene belongs to two pathways: *Interleukin-4 and 13 signaling* and *Interleukin-10 signaling*, and yet none of the two pathways is identified as a significant mechanism for this cell type and multimorbidity (because when considering all the pathway-associated genes, neither pathways is found to be significantly perturbed). Thus, we can conclude that *IL13* may play and important role as a multimorbidity mediator. Our results also provide valuable information of cell-type-specificity of candidate genes. For instance, *IL4* and *IL5*, two of the main inflammatory cytokines, in are associated to monocytes but not to macrophages ([S10 Table](#pone.0224448.s012){ref-type="supplementary-material"}), in agreement with previous observations \[[@pone.0224448.ref110]\].

The only non-cytokine-related gene in the top 10 positions of [Table 5](#pone.0224448.t005){ref-type="table"} is the *PLA2G7* gene, which controls inflammation though the inactivation of platelet-activating factor (*PAF*), a potent phospholipid-derived mediator of inflammation that is secreted by many immune cells and controls vascular permeability. Although no study associating *PLA2G7* to ADR multimorbidity exists, it is a strong candidate if we take into account the wide range of actions of *PAF* (considered a universal biological regulator \[[@pone.0224448.ref111]\]) that in turn associates *PLA2G7* to a number of inflammatory conditions other than A, D or R \[[@pone.0224448.ref112]--[@pone.0224448.ref114]\]. The \"United Airways\" concept, introduced in the previous section, is also supported by our results: on average, mechanisms mediating between A and R are more closely-knit (represented by higher average scores) than mechanisms mediating A and D, although A and D share more disease-associated genes ([Table 1](#pone.0224448.t001){ref-type="table"}).

Some of the highest-scoring candidate genes were not even associated to any of the diseases of interest ([Table 6](#pone.0224448.t006){ref-type="table"}) illustrating the potential of our approach to characterize yet-undescribed molecular mechanisms of multimorbidity. We predict interleukin receptors *IL22RA1* and *IL20RA* to play an important role in the ADR multimorbidity in the esophageal epithelium. To date, *IL22RA1* had been only associated to inflammatory responses in airway epithelia by genetic studies, and *IL20RA* to psoriasis \[[@pone.0224448.ref115], [@pone.0224448.ref116]\]. Also, the functional nature of genes in [Table 6](#pone.0224448.t006){ref-type="table"} is also much more diverse than that of [Table 5](#pone.0224448.t005){ref-type="table"}. This is strongly suggestive of a research bias towards already-known cytokine-related mediators when it comes to the study of these allergic diseases, overlooking other functional groups. For instance, the second highest-scoring gene in [Table 6](#pone.0224448.t006){ref-type="table"} is butyrylcholinesterase *BCHE*, a poorly-studied detoxifying enzyme that has been proposed as a marker to identify and prognose systemic inflammation \[[@pone.0224448.ref117], [@pone.0224448.ref118]\] and that has only marginally associated to allergic diseases. *BCHE* is highlighted by our method as a mediator in ADR multimorbidity in skin. [Table 6](#pone.0224448.t006){ref-type="table"} also shows that the role of proteoglycans seems to be restricted to AR multimorbidity only through neurocan (*NCAN*) and chondroitin sulfate proteoglycan 5 (*CSPG5*). Although proteoglycans are known to influence the remodelling of nasal mucosa in R \[[@pone.0224448.ref119]\], no evidence exists linking them to allergic multimorbidity. However, our results indicate that TLRs are characteristically associated to multimorbidity involving R ([Table 4](#pone.0224448.t004){ref-type="table"}), so there may be an interesting link between TLRs and proteoglycans in relation to AR multimorbidity, since it is known that chondroitin sulfate proteoglycans have the ability to bind TLRs and activating macrophages \[[@pone.0224448.ref120]\].

Comparison to our previous study {#sec029}
--------------------------------

In our previous *in silico* study of multimorbidity between A, D and R, we explored multimorbidity at whole organism level \[[@pone.0224448.ref021]\]. In this study we incorporated additional data that reflects the spatial cell-type-specific nature of the diseases and their multimorbidity. This presents a key opportunity to better understand the mechanisms of diseases, since cell-type-specific data provides a more accurate picture of multimorbidity. We incorporated changes in the methodology as well. It remains focused on exploiting the topology of the interactome, but adopting a more complex approach that measures the role of pathways not only in terms of their direct interactions to individual disease-associated genes, but in terms of their global connectivity to those genes within a specific network.

Methodologically, differences in the gene-disease data sources used in both studies have an impact in the characterization of disease-associated genes. Also, availability of expression data limited the number of genes present in the study. For instance, thymic stromal lymphopoietin (*TSLP*), found to be associated to A, D and R in our previous study, is absent in this study because it was not present in the expression compendium. Also, pathway annotation in our previous study was extracted from BioCarta database, which is no longer updated, which made us chose Reactome database instead.

One of the main findings in our previous study was the significant role of eosinophilic-mediated pathways in AD multimorbidity (BioCarta pathways *CCR3 signaling in Eosinophils* and *The Role of Eosinophils in the Chemokine Network of Allergy* were identified with a high score). Because eosinophils were not included in the present study, the Reactome equivalents of those pathways ([S1 Table](#pone.0224448.s003){ref-type="supplementary-material"}) are not present in our results, confirming that our observations can be linked to mechanisms mediated by other cell types. *IL10* signaling pathway, a relevant mechanism in AD multimorbidity across many cell types, was also identified amongst the highest-scoring pathways in our previous study (under the BioCarta denomination *Regulation of hematopoisesis by cytokines*). Our previous study also linked *IL4*-mediated, *GATA3*-mediated mechanisms and 4--1BB-dependent immune responses to ADR multimorbidity. *GATA3*-mediated mechanisms are represented in our dataset by interleukin pathways in the *Cytokine signaling in immune system* category, and, from a cell-type-specific point of view, these processes seem more relevant in AD multimorbidity (despite the fact that *IL1*, *IL4* and *IL13* signaling in particular also contribute to ADR multimorbidity in some cell types). Aside from differences in pathway annotation of genes, this could reflect a more systemic role for these pathways in ADR multimorbidity. However, *4--1BB-dependent immune response* (represented by Toll-like receptor cascades in our dataset) is clearly associated to AR, DR and ADR multimorbidity in a number blood-derived cell types. In all, we believe that our results are complementary to those of our previous study since they focus on the cell-type-specific mechanisms of multimorbidity instead of global (or systemic) ones.

Conclusions {#sec030}
===========

We designed an *in silico* approach that integrated current public expression and network interaction databases and applied an interactome-based analysis to uncover the cell-type-specific pathophysiological mechanisms of multimorbidity between A, D and R. We observed that interleukin-mediated signaling is present in all multimorbidities involving asthma but not rhinitis, while rhinitis-associated multimorbidities have a strong TLR-mediated component. *IL1* signaling is the only type-2 pathway candidate for AR multimorbidity, found in esophageal epithelium. We also generated a collection of genes potentially linked to cell-type-specific multimorbidity, some of which were not previously associated to any of the diseases. Our results provide a better understanding of the pathophysiological mechanisms triggering ADR multimorbidity, assisting in the design of new mechanistic and clinical studies.

Supporting information {#sec031}
======================

###### Illustration of the process to calculate cell-type-specific multimorbidity.

This toy example uses a simplified network of the cell type *c*, where we will measure the multimorbidity score *MS* for diseases *d1* and *d2*. The numbers circled in grey correspond to the numbered steps in the section *Calculating cell-type-specific multimorbidity* of *Methods*. **(A)** Genes associated to *dis1* (6, orange border) are given an initial score of 1, while all other genes are given a score of 0. **(B)** The *NetScore* algorithm scores all genes in the network according to their connectivity to the D-associated genes (blue gradient). Genes in closer proximity to *dis1*-associated genes get higher scores. **(C)** The top-scoring genes are selected (in blue). Disease *dis1* has 13 top-scoring genes (*S*^*c*^~*dis1*~). **(D)** Genes associated to *dis2* (5, in orange border) are given an initial score of 1, while all other genes are given a score of 0. **(E)** The *NetScore* algorithm scores all genes according to their connectivity to the *dis2*-associated genes (blue gradient). **(F)** The top-scoring genes are selected (in blue). Disease *dis2* has 47 top-scoring genes (*S*^*c*^~*dis2*~). **(G)** There is 1 gene common to both top-scoring sets (in blue). The Multimorbidity Score (*MS*) of the diseases is calculated as the Sorensen-Dice overlap between their top-scoring gene sets. In this case, *MS*^*c*^~*dis1*,*dis2*~ is (2 · 1) / (6 + 47) = 0.038. A permutation test over 10^3^ iterations will establish if *MS*^*c*^~*dis1*,*dis2*~ is statistically significant (*P* \< 0.05).

(PNG)

###### 

Click here for additional data file.

###### Illustration of the process to characterize cell-type-specific multimorbidity mechanisms.

This example uses the network of [S1 Fig](#pone.0224448.s001){ref-type="supplementary-material"} (225 genes). The pathway *P* has a total of annotated 20 genes, of which 9 are in the network (shown in orange border). **(A)** The 13 top-scoring genes for disease *d1* (*S*^*c*^ ~*d1*~; see [S1C Fig](#pone.0224448.s001){ref-type="supplementary-material"}) are shown in blue, and there are 3 pathway genes within this set. Thus, the perturbation score *PS*^*c*^ ~*d1*,*P*~ is (9/20) / (13/225) = 7.79. For the sake of the example, we will assume that this value is significantly larger than random expectation (*P* \< 0.05). **(B)** The 47 top-scoring genes for disease *d2* (*S* ^c^~*d2*~; see [S1F Fig](#pone.0224448.s001){ref-type="supplementary-material"}) are shown in blue. There are 7 pathway genes within the *S*^*c*^~*d2*~ set. Thus, the perturbation score *PS*^*c*^~*d2*,*P*~ is (9/20) / (47/225) = 2.15. For the sake of the example, we will assume that this value is significantly larger than random expectation as well (*P* \< 0.05). Consequently, because pathway *P* is significantly associated to (or perturbed by) diseases *d1* and *d2*, we assume that it is part of the mechanism of multimorbidity between *dis1* and *dis2* in cell type c.

(PNG)

###### 

Click here for additional data file.

###### Association between Reactome pathways and BioCarta pathways.

Only significant associations are shown. LOR: Log Odds Ratio.

(XLS)

###### 

Click here for additional data file.

###### List of cell-type-specific genes.

This table contains: 1) the database sources of diease-associated genes; 2) the complete list of cell types and tissues (including those without disease-associated genes, discarded in this study); 3) the list of all cell-type-specific genes.

(XLS)

###### 

Click here for additional data file.

###### Fraction of disease-associated genes in each cell type.

Statistical significance was calculated by means of a Fisher's Exact Test.

(XLS)

###### 

Click here for additional data file.

###### Fraction of pathway-associated genes present in each cell type.

(XLS)

###### 

Click here for additional data file.

###### List of genes associated to each pathway in each cell-type-specific network.

(XLS)

###### 

Click here for additional data file.

###### The connectivity *Ccp* of the pathways.

(XLS)

###### 

Click here for additional data file.

###### Summary of Tables [2](#pone.0224448.t002){ref-type="table"} and [3](#pone.0224448.t003){ref-type="table"}.

The column *n diseases* contains the number of diseases (A, D, R) with a significant number of associated genes from [Table 2](#pone.0224448.t002){ref-type="table"} (values are highlighted in blue gradient). The column *n MS \> 0* contains the number of combinations of diseases (AD, AR, DR, ADR) with nonzero *MS* from [Table 3](#pone.0224448.t003){ref-type="table"} (values are highlighted in red gradient). The column *n MS \> 0*.*50* contains the number of combinations of diseases (AD, AR, DR, ADR) with *MS \> 0*.*50* (also from [Table 3](#pone.0224448.t003){ref-type="table"}, highlighted in red gradient).

(XLS)

###### 

Click here for additional data file.

###### Cellular pathways associated to multimorbidity between asthma, dermatitis and rhinitis.

Red cells: multimorbidity between A and D. Orange cells: multimorbidity between A and R. Light blue cells: multimorbidity between D and R. Dark blue cells: multimorbidity between A, D and R. Only cell types not present in [Table 4](#pone.0224448.t004){ref-type="table"} in the manuscript are shown.

(XLS)

###### 

Click here for additional data file.

###### Pathways associated to diseases in the cell-type-specific networks.

A: asthma. D: dermatitis. R: rhinitis. Only significant associations (*P* \< 0.05) are shown.

(XLS)

###### 

Click here for additional data file.

###### Complete list of candidate genes for multimorbidity.

Colors and dots are as in Tables [5](#pone.0224448.t005){ref-type="table"} and [6](#pone.0224448.t006){ref-type="table"} in the manuscript. Pathway associations with a grey background mean that the pathway was not associated to the corresponding cell type (see [Table 4](#pone.0224448.t004){ref-type="table"}, [S8 Table](#pone.0224448.s010){ref-type="supplementary-material"}).

(XLS)

###### 

Click here for additional data file.

###### Comparison of multimorbidity scores.

Scores for AD, AR and DR multimorbidities from [Table 5](#pone.0224448.t005){ref-type="table"} (30 top-scoring genes) and [S10 Table](#pone.0224448.s012){ref-type="supplementary-material"} (all genes) are pairwisely compared by means on a Wilcoxo-Mann-Whitney paired test.

(XLS)

###### 

Click here for additional data file.

###### Supplementary Methods.

(PDF)

###### 

Click here for additional data file.

We thank Judith García-Aymerich, PhD and Emre Guney, PhD for fruitful discussions.

A

:   asthma

AD

:   multimorbidity between asthma and dermatitis

ADR

:   multimorbidity between asthma, dermatitis and rhinitis

AR

:   multimorbidity between asthma and rhinitis

D

:   dermatitis

DR

:   multimorbidity between dermatitis and rhinitis

MS

:   Multimorbidity Score

PS

:   Perturbation Score

R

:   rhinitis
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General remark

This paper reports on an extensive interactome analysis of three disease known to be clinically associated as co-morbidities, asthma, rhinitis and dermatitis. It follows on from their previous paper in this journal but now focuses on phenotypes of disease that distinctly do not involve eosinophils.

Specific comments

1\. This is a study that has used a complex systems biology to integrate data. My main general comment/critique of this paper is that it makes very difficult reading, and makes an assumption that readers will understand the methods and how the data were interpreted. This may well be the case fo a systems biology journal but not for a journal like PLOS which is read widely. I fear that not many people without in-depth knowledge of the methods applied will understand it. I have given some examples below but the whole paper could do with a rewrite to make it more friendly. For example, a standard cell biologist will be puzzled to see that 14 cell types are major components in asthma, rhinitis and dermatitis in 15 distinct tissue sites. It is difficult to comprehend how any tissue outside the lung, the nose and skin (e.g. adipose tissue) is related to any of these diseases.

2\. What do the authors conclude is a major novelty that arises out of their analysis? After so much analysis the conclusions seem very bland: the link between asthma and dermatitis through IL-4 and IL-13 (hardly a novel thing) and TLR-mediated IL1 signaling. No proposal for how the genes previously not associated with these diseases could be involved or targeted.

3\. The key obstacle which took me a while to work around is that the authors state that the data reflects only expression levels in healthy individuals yet the paper is making conclusions about three diseases!

4\. The authors do not provide any no steer for taking the interactome, which is a hypothesis-setting stage, towards definitive proof. One could argue that the only way to do this is to perturb the pathways that are shared across the three diseases.

5\. I found it very annoying to stop and think about what terms like cell type T mean. What does disease d (line 107) mean? I am assuming it means disease-associated but I can't see the value of writing it like this. Why not just say disease-associated. When reading a text, it is annoying to have to go back to the initial definition to see what it means.

1\. Cell type-specific gene expression: I am intrigued to see that only samples not subjected to any treatments were considered. Why? An explanation is needed in the methods or, if more lengthy, in the discussion. Also, why discard whole blood derived data if they are controlled for cell types? I am sure the authors are aware of methods to correct for cell types in a sample containing a mix of cells.

2\. The sentence "Being reactome a hierarchical collection of pathways.." is not clear at all.

3\. Results section, line 285: please state from which databases the disease-gene associations were obtained.

4\. Table 1: the legend needs clarification. The full circles distinguish associations characterised by GWAS ad by other methods. What about associations made by both GWAS and other methods? It would be useful to see a column with the number of methods that show the association.

5\. I am intrigued to see that more gene-disease associations were shared between asthma and dermatitis than between asthma and rhinitis. What does that say about the one airway concept that implies strong links between the upper and lower airways?

6\. Line: 301: We are told that the complete interactome contained 15.332 genes, yet Table 1 only shows a fraction of these as being associated with the three diseases. Does this mean that the other genes (the majority) are NOT associated with the three diseases studied in this paper? If this is correct, then a sentence should be added to explain that we are seeing only a minority of genes associated with the three diseases.

7\. Line 303: We are told that there were 62 cell types. Can we see the list of these cell types or, if Table 2 is the full list, please say so in the text?

8\. Line: 303: Why and how were cells classified into 15 distinct tissues? What tissues are you talking about (the list?)

9\. Table 2 legend: when you say that "the number of genes is significantly high", high compared to what? Is the adjusted p value FDR adjusted?

10\. Line 320: when you say that 519 pathways were available, do you mean that there was evidence for 519 pathways detected in the datasets you examined?

11\. Table 3 shows tissues that have no connection with the three diseases. For example, if we take the first tissue type (adipose tissue from abdomen and thigh, please explain how these data are linked to one of the three diseases?

12\. I am struggling to understand in Table 4 how Erythrocyte pathways are associated with asthma and rhinitis in respect of the adaptive immune system.

Minor comments:

1\. The paper would benefit from proof reading by a native English speaker as there are several minor mistakes in English and punctuation. E.g. abstract: in the methods section error in English "...multimorbidity mechanisms in distinct cell types WERE characterised...., use of the word "coordinately"instead of "in a coordinated manner" (line 60), repetition of "can be shared" (line 75 etc.

Reviewer \#2: The authors investigated mechanisms explaining the multimorbidity between asthma, dermatitis and rhinitis and their specificity in distinct cell types by means of an interactome-based analysis of expression data. The authors observed differential roles for cytokine signaling, TLR-mediated signaling and distinct metabolic pathways across distinct cell types. This paper is a continuation of their previous study, where they explored multimorbidity between asthma, dermatitis and rhinitis at whole organism level by investigating patterns of network connectivity between cellular networks.

The paper is well written and data is clearly presented. Data in tables are well presented but figures are not clear. I recommend uploading higher resolution images. The discussion does a nice job of putting the results into context of previous studies. However, it would be good to discuss also other genes for which a significant link has been shown. For example, it would be interesting if you could discuss what is known about PLA267 gene so far in the context of these multimorbidities.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to the Reviewers

When thank the reviewers for their deep review of our manuscript and their useful criticisms and recommendations. We have done our best to have all comments carefully considered and approached.

Reviewer \#1

This paper reports on an extensive interactome analysis of three disease known to be clinically associated as co-morbidities, asthma, rhinitis and dermatitis. It follows on from their previous paper in this journal but now focuses on phenotypes of disease that distinctly do not involve eosinophils.

Specific comments

COMMENT \#1-A. This is a study that has used a complex systems biology to integrate data. My main general comment/critique of this paper is that it makes very difficult reading, and makes an assumption that readers will understand the methods and how the data were interpreted. This may well be the case of a systems biology journal but not for a journal like PLOS which is read widely. I fear that not many people without in-depth knowledge of the methods applied will understand it. I have given some examples below but the whole paper could do with a rewrite to make it more friendly.

AUTHORS\' ANSWER: It is true that our methodology is highly technical and may look abstruse to readers unfamiliar with bioinformatics who are, nonetheless, interested in our study. In order to make the text more friendly to non-specialists, we perused the manuscript (and the Methods section in particular) assisted by the expertise of Dr Jean Bousquet (Editor-in-Chief of Clinical Translational Allergy, and member of the editorial board of a number of journals in the fields of allergy and immunology \[<https://ctajournal.biomedcentral.com/about/editorial-board/jean-bousquet>\]). We moved the more technical parts of Methods to a supplementary file (S1 Text) while keeping in the main manuscript a more plain description of the methodology, hopefully easier to follow by non-specialists. For the sake of accuracy, we had to keep some technicalities in the descriptions (e.g. some abbreviations).

Our journal choice followed the acceptance and publication of our previous paper \[Aguilar, 2017\] which was also an in silico method of similar complexity. We believe that this is not an insolvable problem in a journal such as PLOS ONE, where in-silico-only studies are routinely published, describing complex computational procedures based on machine learning, neuronal systems, prediction software or algorithmics \[Kulikovskikh, 2019; Parashar, 2019; Mirabello, 2019; Ingrossom 2019; Gearing, 2019; Shtar, 2019; just to name a recent few\].

COMMENT \#1-B. For example, a standard cell biologist will be puzzled to see that 14 cell types are major components in asthma, rhinitis and dermatitis in 15 distinct tissue sites. It is difficult to comprehend how any tissue outside the lung, the nose and skin (e.g. adipose tissue) is related to any of these diseases.

AUTHORS\' ANSWER: We agree with the reviewer. The involvement of 14 cell types in 15 tissues may sound puzzling to a conventional reader. However this is part of the novelty and an accepted possibility in the systems medicine. A, D and R are complex systemic diseases affecting a wide range of bodily systems through inflammatory-related processes.

Our aim with this study was to systematically assess the involvement of all available cell types in our dataset in the mechanisms of ADR multimorbidity (instead of focusing only on those for which evidence had been previously reported). We believe that by doing so we could potentially suggest new mechanisms or predict the clinical expression of multimorbidity in unexpected novel locations, providing researchers with new insights and directions to explore the molecular nature of ADR multimorbidity.

In this respect, Table 3 does not show the relationship between a disease and a cell type, but the degree with which multimorbidity is manifested in a given cell type (as MS score, ranging from 0 to 1). There are 14 cell types where MS is \> 0, suggesting some degree of involvement. However, this does not mean that all these cell types are \"major components\" of multimorbidity. For instance, kidney epithelium has a score of 0.11, which implies a non-zero but nonetheless low impact of ADR multimorbidity in this cell type, owing probably to its epithelial nature (which is shared with other epithelia where multimorbidity has a stronger manifestation, such as the esophageal epithelium). We rewrote the Quantification of cell-type-specific multimorbidity section in Results to acknowledge this fact (line 286):

Inspection of Table 3 shows 14 cell types associated to ADR multimorbidity because their MS value is \> 0 for all combinations of the three diseases (the strength of the association given by the MS value, ranging from 0 to 1).

Re to the particular example of the adipose tissue, there is evidence linking it to inflammation-related conditions through low-grade inflammatory processes \[Ouchi, 2011; Greenberg, 2006; Karczewski, 2018\], and excess body mass has been linked to the risk of development of asthmatic symptoms \[Leiria, 2015; Muc, 2016\]. This link has been studied mostly for asthma \[Backer, 2016\], although there is also evidence of dermatitis-related diseases \[Nagel, 2009\].

COMMENT \#2. What do the authors conclude is a major novelty that arises out of their analysis? After so much analysis the conclusions seem very bland: the link between asthma and dermatitis through IL-4 and IL-13 (hardly a novel thing) and TLR-mediated IL1 signaling. No proposal for how the genes previously not associated with these diseases could be involved or targeted.

AUTHORS\' ANSWER: We think that the novelty of our study is two-fold:

First, this is the first study to our knowledge to systematically assess the involvement of many different cells and tissues on the development of ADR multimorbidity. So far, the study of these conditions has been focused in a few cell types (such as eosinophils). To our knowledge, this is the first time that a cell-type-wide landscape of allergic multimorbidity is produced, and our results show that non-eosinophilic cell types have a role in the manifestation of multimorbidity.

Second, we identified specific molecular mechanisms for multimorbidity depending whether rhinitis is present or not: while interleukin-mediated signaling seems to be in the basis of all asthma-involving multimorbidities, the role of TLR-mediated signaling is largely absent when rhinitis is not present as one of the multimorbid diseases. We rephrased the Conclusions to highlight this fact (line 598):

We observed that interleukin-mediated signaling is present in all multimorbidities involving asthma but not rhinitis, while rhinitis-associated multimorbidities have a strong TLR-mediated component.

As to novel gene candidates, Tables 5, 6 and S10 provide lists of candidate genes potentially associated to multimorbidity. Table 6, in particular, provides a list of candidate genes not yet associated to any of the diseases, which makes them particularly interesting subjects of study. However, owing to the large number of potential candidates, we only briefly described a few of the top-scoring ones (namely, IL1RL1, IL13, IL22RA1 and IL20RA). Following the reviewers\' suggestions, we expanded the Cell-type-specific candidate genes section in Discussion to include PLA2G7 (the only non-cytokine-related gene among the top 10 in Table 5) and BCHE and proteoglycans NCAN and CSPG5 from Table 6.

COMMENT \#3. The key obstacle which took me a while to work around is that the authors state that the data reflects only expression levels in healthy individuals yet the paper is making conclusions about three diseases!

AUTHORS\' ANSWER: We agree with the reviewer: it seems hardly possible to infer anything about the mechanisms of diseases by studying the gene expression in healthy subjects. However, this is a standard procedure in interactome-based in silico studies of disease, which face unavoidable limitations in data availability. In our case, those limitations were:

1\) To the best of our knowledge, there is not a single expression data study for ADR across multiple tissues/cell types (we discarded merging expression studies from different origins because of the unsurmountable level of data noise it would have added due to technical variation).

2\) We lack interactomic data for individuals with ADR (and this is true for many other diseases: the \"diseased\" interactome is largely undescribed).

Thus, our methodology was designed to convey the disease-related information not in the gene expression levels or the interactome, but in the disease-associated genes. The result is that our study measures how disease (i.e. malfunctioning genes) perturbs the normal (i.e. healthy) cellular mechanisms, represented by the cell-type-specific interactome.

This methodology (and variations thereof) has been extensively used in in silico studies of disease, with remarkable results \[Goh, 2007; Vidal, 2011; Bashir, 2014; Kitsak, 2016; Huttlin, 2017\]. In a recent review, Sonawane et al. examined how the "healthy" interactome can be mined for the localization of the disease perturbation, better disease sub-type classifications, and better targets for drug development \[Sonawane, 2019\]. Furthermore, studies and software tools predicting novel disease-associated genes rely on similar methodologies \[Guney 2014; Ghiassian, 2015; Huttlin, 2017; just to name a few\].

A statistical comparison of our results to those obtained from the analysis of gene expression and the interactome data of diseased individuals would have been really interesting. However, the above-mentioned limitations make it impossible. This is why in the Discussion section we compared our findings to those found in literature through a case-by-case manual revision of previous studies.

COMMENT \#4. The authors do not provide any no steer for taking the interactome, which is a hypothesis-setting stage, towards definitive proof. One could argue that the only way to do this is to perturb the pathways that are shared across the three diseases.

AUTHORS\' ANSWER: Certainly, our objective was to \"perturb\" the pathways and statistically measure the degree to which those perturbations could lead to multimorbidity in distinct cell types (see COMMENT \#3). The lack of an experimental stage in fully computational studies like ours makes them more oriented towards setting new hypothesis and guiding new experiments (see references in COMMENT \#1-A). Consequently, our results are predictions to guide further experimental research towards the discovery of new disease-related genes, as has long been one of the main tasks of Bioinformatics \[see Yo, 2008; Kann, 2010; Ferrero, 2017; van Dam, 2018 and references therein\]. Throughout in the Discussion we highlighted how our predictions agreed with experimental evidences from literature. We have now emphasized the hypothesis-setting role of out study with the following sentence in Strengths section in the Discussion (line 388):

The findings of this in silico study are hypothesis-generating and are intended to guide new experiments on cell-type-specific allergic multimorbidity. Consequently, they should be confirmed by proper mechanistic and genetic studies.

COMMENT \#5. I found it very annoying to stop and think about what terms like cell type T mean. What does disease d (line 107) mean? I am assuming it means disease-associated but I can't see the value of writing it like this. Why not just say disease-associated. When reading a text, it is annoying to have to go back to the initial definition to see what it means.

AUTHORS\' ANSWER: Line 107 said: \"Genes associated to a disease d (any of A, D or R) will be hereinafter referred to as d-associated genes.\" Hence, a d-associated gene is a gene associated to A, D or R. Similarly, line 148 said: \"Genes specific to a cell type T (any of our cell types of interest) will be hereinafter referred to as T-specific genes\".

We discarded the term \"disease-associated gene\" because it was too ambiguous for an accurate description of some parts of the methodology (what disease would it be referring to?). For the same reasons, we discarded using \"cell-type-specific network\". Furthermore, the formulae that we employ in the Methods section use those same abbreviations. However, it is true that the term \"cell type T\" can be confusing, since T cells are a major cell type associated to immune system. This is why we changed it to \"cell type c\". Also, we rewrote the manuscript to ensure that most of those abbreviations are mostly restricted to the supplementary Methods (S1 Text) only, keeping them down to a minimum in the main text.

COMMENT \#6-A. Cell type-specific gene expression: I am intrigued to see that only samples not subjected to any treatments were considered. Why? An explanation is needed in the methods or, if more lengthy, in the discussion.

AUTHORS\' ANSWER: For consistency, it is generally not advisable to combine expression data from healthy individuals with data from patients undergoing a treatment or exposed to some environmental factor. The original expression dataset included data for individuals after alcohol consumption, after sugar consumption, exposed to UV, treated with DMSO, treated with TFG-b1, etc. Aside from the fact that all these treatments and exposures are unrelated to the diseases under study (except maybe for TFG-b1), mixing them with data from healthy individuals would have added noise to the gene expression levels without adding any benefit that we can see.

We added a clarifying sentence in S1 Text (supplementary Methods):

In order to maximize consistency and avoid noise in the gene expression levels, only adult human samples and cell types not subjected to any treatments (e.g. treated with DMSO) neither exposed to particular environmental factors (e.g. tobacco smoke, UV) were considered.

COMMENT \#6-B. Also, why discard whole blood derived data if they are controlled for cell types? I am sure the authors are aware of methods to correct for cell types in a sample containing a mix of cells.

AUTHORS\' ANSWER: Yes, there are methods to separate individual cell-types in heterogeneous gene expression data but most of them perform deconvolution-based enrichment analysis (CIBERSORT, X-CELL, LinSeed). In our case, identifying the relative frequencies of cell types within the whole blood \"tissue\" would have not helped, since we need to know the actual expression levels of all the genes for every cell type and, to our knowledge, no software tool performs this. Furthermore, even if such a tool existed, it would simply provide a statistical estimation of gene expression levels, and we did not wish to draw biological predictions from data which was, in turn, a prediction.

However, most of the major cell types typically associated to whole blood (neutrophils, monocytes/macrophages, lymphocytes, erythrocytes) were already present individually in the expression study. The only exception was eosinophils, but, as we stated in the discussion, its role in ADR multimorbidity has been studied extensively, so we chose to focus on other lesser studied cell types.

COMMENT \#7. The sentence "Being reactome a hierarchical collection of pathways.." is not clear at all.

AUTHORS\' ANSWER: Rewritten to (line 138):

Reactome is a collection of pathways built in a hierarchical manner, where larger pathways are subdivided into smaller pathways with more specific functionalities.

COMMENT \#8. Results section, line 285: please state from which databases the disease-gene associations were obtained.

AUTHORS\' ANSWER: It\'s in the Methods section \> Data sources \> Gene-disease associations. We rewrote the text to point the reader to that section (line 227):

The complete list of genes is shown in Table 1 (see Table S2 and Gene-disease associations in the Methods section for data sources).

COMMENT \#9. Table 1: the legend needs clarification. The full circles distinguish associations characterised by GWAS ad by other methods. What about associations made by both GWAS and other methods? It would be useful to see a column with the number of methods that show the association.

AUTHORS\' ANSWER: We agree, the text of the legend in Table 1 was confusing. It was rewritten and now reads:

Table 1. Gene-disease associations. A: asthma; D: dermatitis; R: rhinitis. Filled circle: all evidences. Empty circle: GWAS-only evidence. Only genes with expression data, present in the interactome and associated to A, D or R are shown.

Re to the number of distinct methods of characterization, this is a kind of information that is not explicitly provided in the databases that we used (with the exception of PheGenI, which contains only GWAS-based associations). Supplementary Table S2 now shows the database(s) from where the associations were extracted.

COMMENT \#10. I am intrigued to see that more gene-disease associations were shared between asthma and dermatitis than between asthma and rhinitis. What does that say about the one airway concept that implies strong links between the upper and lower airways?

AUTHORS\' ANSWER: Not all gene-disease associations have the same clinical impact. Particularly in complex diseases, the molecular relationship between an altered gene and the manifestation of a disease can take many forms, which translates into some genes having a larger impact in the disease than others. We are not aware of any kind of metric measuring the clinical impact of a gene-disease association, and sometimes (for instance in GWAS studies) the nature of this molecular relationship can only be assumed. On top of this, different databases have different criteria as to incorporate gene-disease associations. For these reasons, 1) Table 1 provides the gene-disease associations but does not quantify them in terms of clinical impact, and 2) it is entirely possible for asthma and rhinitis to have a stronger molecular relationship (sharing only 8 genes) than asthma and dermatitis (sharing 22 genes).

We partially addressed that problem by analyzing multimorbidity at interactome level instead of gene level. Interactome-based studies have shown that topology in the network can be used as a proxy for clinical impact (the alteration of a more central gene is likely to have a larger impact in the surrounding interactome) \[Jeong 2001; Vidal, 2011; Carson, 2015; Park, 2019; just to name a few\]. So, our multimorbidity scores can be interpreted as a measure of the impact of a gene in multimorbidity. Tables 5 and 6 (which are top-scoring subsets of Table S10) show that, for the same gene, scores for AR multimorbidity tend to be larger than scores for AD multimorbidity (statistical comparison in newly-added Table S11). This suggests that the molecular relationship between asthma and rhinitis is stronger than the relationship between asthma and dermatitis despite having less shared gene in Table 1.

We have expanded the Candidate multimorbidity genes section in Results to acknowledge this fact (line 331):

Genes in Table 5 show a higher score, on average, for AR than for AD multimorbidity (P = 0.01482; paired Wilcoxon-Mann-Whitney test), implying a more closely-knit biological mechanism for AR than for AD multimorbidity. The same was observed for AD vs DR (P = 1.02·10-3; paired Wilcoxon-Mann-Whitney test) but not for AR vs DR. This observation was also true when comparing scores of the whole set of predicted genes in S10 Table.

We also expanded the Cell-type-specific candidate genes section in Discussion (line 536):

The \"United Airways\" concept, introduced in the previous section, is also supported by our results: on average, mechanisms mediating between A and R are more closely-knit (represented by higher average scores) than mechanisms mediating A and D, despite the fact that A and D share more disease-associated genes (Table 1).

Lastly, we cannot rule out the presence of a research bias: asthma and dermatitis have been much more studied than rhinitis (a quick PubMed search retrieves 182,260 entries for asthma, 120,033 entries for dermatitis, and 43,007 entries for rhinitis). This suggests a larger number of disease-associated genes known for asthma and dermatitis, which in turns increases the chance of a larger overlap.

COMMENT \#11. Line: 301: We are told that the complete interactome contained 15.332 genes, yet Table 1 only shows a fraction of these as being associated with the three diseases. Does this mean that the other genes (the majority) are NOT associated with the three diseases studied in this paper? If this is correct, then a sentence should be added to explain that we are seeing only a minority of genes associated with the three diseases.

AUTHORS\' ANSWER: Yes, only a small fraction of the genome is associated to A, D or R. Naturally, we cannot rule out that in the future new genes will be associated to A, D or R (they certainly will) but we reflected the state of the knowledge at the present moment.

Table 1 shows the genes associated to at least one of the diseases. The legend has been rewritten to clarify this fact (see answer to COMMENT \#9).

COMMENT \#12. Line 303: We are told that there were 62 cell types. Can we see the list of these cell types or, if Table 2 is the full list, please say so in the text?

AUTHORS\' ANSWER: Table 2 only shows those cell types where at least one disease-associated gene has been found. So, the last sentence in Table 2 legend has been rewritten as:

For clarity, zero values are represented as blank cells, and cell types without any disease-associated genes are not shown.

Although tissues and cell types are part of the information provided in Table S2, for clarity we have expanded Supplementary Table S2 with the list of tissues and cell types only. In creating this table, we realized that the total number of cell types was 60, not 62 (after the removal of generic cell types peripheral blood leukocytes and peripheral blood mononuclear cells, see Methods). This figure has been corrected in lines 241 and 284 in the text.

COMMENT \#13. Line: 303: Why and how were cells classified into 15 distinct tissues? What tissues are you talking about (the list?)

AUTHORS\' ANSWER: The classification of cell types into tissues was obtained from the original expression study E-MTAB-62 \[<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-62/>\]. Supplementary Table S2 provides the complete list of tissues as well as their corresponding cell types.

COMMENT \#14. Table 2 legend: when you say that "the number of genes is significantly high", high compared to what? Is the adjusted p value FDR adjusted?

AUTHORS\' ANSWER: In Table 2, the sentence \"the number of genes is significantly high\" means that the number of genes is significantly higher than random expectation. Throughout the paper, the term \"significant\" is always associated to statistical significance. We have rephrased the legend accordingly.

As explained in Methods, we adjusted P-values with the Benjamini-Hochberg method, which controls the False Discovery Rate (FDR) \[Haynes, 2013\]. We rewrote the first mention of the method to acknowledge this (line 154). Now reads:

\[\...\] adjusted by the Benjamini-Hochberg method for false discovery (FDR) control.

COMMENT \#15. Line 320: when you say that 519 pathways were available, do you mean that there was evidence for 519 pathways detected in the datasets you examined?

AUTHORS\' ANSWER: No, we meant that 519 were available in the Reactome database after removing overlapping pathways. The line has been rewritten as (line 261):

The number of pathways in Reactome database was 519 after filtering, with an average pairwise overlap of 0.01%.

COMMENT \#16. Table 3 shows tissues that have no connection with the three diseases. For example, if we take the first tissue type (adipose tissue from abdomen and thigh, please explain how these data are linked to one of the three diseases?

AUTHORS\' ANSWER: This study was not aimed to explore the mechanisms of single diseases, but only the mechanisms of multimorbidity between pairs/trios of diseases (i.e. AD, AR, DR, ADR). As explained in Methods, two diseases were considered to display multimorbidity in a certain cell type if (1) they both were manifested individually in the cell type, and (2) they perturbed pathways that overlapped (implying that the manifestation of one disease can be "transmitted" as a perturbation through the pathway and cause the manifestation of the other, hence the multimorbidity). The MS score in Table 3 numerically measures that overlap. We have rewritten the \"Quantification of cell-type-specific multimorbidity\" paragraph in Results to clarify this (see COMMENT \#1-B).

In Table 3, empty cells mean that no perturbed pathways have been found overlapping between diseases (hence, MS = 0). For instance, for the first cell type \"adipose tissue from abdomen and thigh\", we found a possible mechanism for multimorbidity between A and D (described in Table 4 as related to interleukin-4, -10, and -13). However, we didn\'t identify any mechanism for multimorbidity between A-R, D-R or A-D-R for this cell type. In the answer to COMMENT \#\#1-B we provided some references for studies of the association between these diseases and adipose tissue.

COMMENT \#17. I am struggling to understand in Table 4 how Erythrocyte pathways are associated with asthma and rhinitis in respect of the adaptive immune system.

AUTHORS\' ANSWER: This is due to a limitation in our study, related to the very definition of what a pathway is. It is known that nonnucleated cells (such as the erythrocyte) express little or no MHC. However, according to Reactome database two asthma-associated genes (CD14, TLR1) and three rhinitis-associated genes (CD14, TLR1, TLR2) are associated to the pathway \"Antigen processing-Cross presentation\", and we found them specifically expressed in erythorcytes. The reason for this is probably the broad definition of what constitutes the \"Antigen processing-Cross presentation\" pathway in Reactome database, which includes genes belonging to other pathways not related to the adaptative immune system. In particular, TLR1, TL2 and CD14 are also present in a number of Toll-like receptor cascades, found to be active in erythrocytes \[Anderson, 2018; Hotz, 2018\]. Since the limits of what can be and cannot be considered as a part of a pathway is always open to discussion (with the possible exception of some classical pathways such as the Krebs Cycle), we chose to use the pathways as they were defined in Reactome database, removing only those with a large overlap (\> 50% of genes in common). We have modified the Discussion to acknowledge this fact (line 474):

We have to point out, however, that the definition of a pathway (as a functionally annotated gene set) should be taken into account when analyzing those results. For instance, the pathway Antigen Processing and Cross-Presentation is associated to AR multimorbidity in erythrocytes (Table 4) contradicts evidence on MHC presence in human nonnucleated cells \[93\] because of the definition of the pathway in Reactome database, that includes genes also annotated in TLR-mediated pathways.

Minor comments:

COMMENT \#18. The paper would benefit from proof reading by a native English speaker as there are several minor mistakes in English and punctuation. E.g. abstract: in the methods section error in English "...multimorbidity mechanisms in distinct cell types WERE characterised...., use of the word "coordinately"instead of "in a coordinated manner" (line 60), repetition of "can be shared" (line 75 etc.

AUTHORS\' ANSWER: We have proof-read all texts to correct any mistakes. However, according to <https://www.dictionary.com> (which is based on the Random House Unabridged Dictionary), the adverb \"coordinately\" is correct.

Reviewer \#2

COMMENT \#1. The authors investigated mechanisms explaining the multimorbidity between asthma, dermatitis and rhinitis and their specificity in distinct cell types by means of an interactome-based analysis of expression data. The authors observed differential roles for cytokine signaling, TLR-mediated signaling and distinct metabolic pathways across distinct cell types. This paper is a continuation of their previous study, where they explored multimorbidity between asthma, dermatitis and rhinitis at whole organism level by investigating patterns of network connectivity between cellular networks.

The paper is well written and data is clearly presented. Data in tables are well presented but figures are not clear. I recommend uploading higher resolution images. The discussion does a nice job of putting the results into context of previous studies. However, it would be good to discuss also other genes for which a significant link has been shown. For example, it would be interesting if you could discuss what is known about PLA267 gene so far in the context of these multimorbidities.

AUTHORS\' ANSWER: Images were checked for resolution using the PACE software, as requested by the journal's guidelines. All of them passed the quality control. However, the pdf generated for revision contains lower-quality versions of the figures (in order to keep the file size within reasonable limits). A better-quality version of the figure can be downloaded by clicking on the link on the upper right corner of each page.

Because the number of candidate genes was rather long, we chose to focus on those with scarcer previous evidence of association with the diseases under study. However, at the reviewer\'s request, we have extended the Cell-type-specific candidate genes section in the Discussion to include PLA2G7. We have also extended the section by commenting on the cell type specificity of IL4 and IL5 and by pointing out the higher scores of genes associated with AR multimorbidity when compared to AD multimorbidity, linking this fact to the \"United Airways\" concept that established a strong mechanistic connection between asthma and rhinitis. The additional text reads (line 530 onwards):

The only non-cytokine-related gene in the top 10 positions of Table 5 is the PLA2G7 gene, which controls inflammation though the inactivation of platelet-activating factor (PAF), a potent phospholipid-derived mediator of inflammation that is secreted by many immune cells and controls vascular permeability. Although no study associating PLA2G7 to ADR multimorbidity exists, it is a strong candidate if we take into account the wide range of actions of PAF (considered a universal biological regulator \[111\]) that in turn associates PLA2G7 to a number of inflammatory conditions other than A, D or R \[112-114\]. The \"United Airways\" concept, introduced in the previous section, is also supported by our results: on average, mechanisms mediating between A and R are more closely-knit (represented by higher average scores) than mechanisms mediating A and D, although A and D share more disease-associated genes (Table 1).

Some of the highest-scoring candidate genes were not even associated to any of the diseases of interest (Table 6) illustrating the potential of our approach to characterize yet-undescribed molecular mechanisms of multimorbidity. For instance, we predict interleukin receptors IL22RA1 and IL20RA to play an important role in the ADR multimorbidity in the esophageal epithelium. To date, IL22RA1 had been only associated to inflammatory responses in airway epithelia by genetic studies, and IL20RA to psoriasis \[115, 116\]. Also, the functional nature of genes in Table 6 is also much more diverse than that of Table 5. This is strongly suggestive of a research bias towards already-known cytokine-related mediators when it comes to the study of these allergic diseases, overlooking other functional groups. For instance, the second high-scoring gene in Table 6 is butyrylcholinesterase BCHE, a poorly-studied detoxifying enzyme that has been proposed as a marker to identify and prognose systemic inflammation \[117, 118\] and that has only marginally associated to allergic diseases. BCHE is highlighted by our method as a mediator in ADR multimorbidity in skin. Table 6 also shows that the role of proteoglycans seems to be restricted to AR multimorbidity only through neurocan (NCAN) and chondroitin sulfate proteoglycan 5 (CSPG5). Although proteoglycans are known to influence the remodelling of nasal mucosa in R \[119\], no evidence exists linking them to allergic multimorbidity. However, our results indicate that TLRs are characteristically associated to multimorbidity involving R (Table 4), so there may be an interesting link between TLRs and proteoglycans in relation to AR multimorbidity, since it is known that chondroitin sulfate proteoglycans have the ability to bind TLRs and activating macrophages \[120\].
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